WO2005046517A1 - Cardiac harness - Google Patents

Cardiac harness Download PDF

Info

Publication number
WO2005046517A1
WO2005046517A1 PCT/US2004/035256 US2004035256W WO2005046517A1 WO 2005046517 A1 WO2005046517 A1 WO 2005046517A1 US 2004035256 W US2004035256 W US 2004035256W WO 2005046517 A1 WO2005046517 A1 WO 2005046517A1
Authority
WO
WIPO (PCT)
Prior art keywords
expansion
harness
heart
percent
cardiac harness
Prior art date
Application number
PCT/US2004/035256
Other languages
French (fr)
Inventor
Lilip Lau
Anuja Patel
Original Assignee
Paracor Medical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paracor Medical, Inc. filed Critical Paracor Medical, Inc.
Priority to CA002541890A priority Critical patent/CA2541890A1/en
Priority to EP04818599A priority patent/EP1677702A1/en
Priority to JP2006538143A priority patent/JP2007512040A/en
Publication of WO2005046517A1 publication Critical patent/WO2005046517A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2478Passive devices for improving the function of the heart muscle, i.e. devices for reshaping the external surface of the heart, e.g. bags, strips or bands
    • A61F2/2481Devices outside the heart wall, e.g. bags, strips or bands

Definitions

  • the present invention relates to a device for treating heart failure. More specifically, the invention relates to a cardiac harness configured to be fit around at least a portion of a patient's heart.
  • DESCRIPTION OF THE RELATED ART Congestive heart failure (“CHF") is characterized by the failure of the heart to pump blood at sufficient flow rates to meet the metabolic demand of tissues, especially the demand for oxygen.
  • CHF Congestive heart failure
  • One characteristic of CHF is remodeling of at least portions of a patient's heart. Remodeling involves physical changes to the size, shape and thickness of the heart wall. For example, a damaged left ventricle may have some localized thinning and stretching of a portion of the myocardium.
  • the thinned portion of the myocardium often is functionally impaired, and other portions of the myocardium attempt to compensate.
  • the other portions of the myocardium may expand so that the stroke volume of the ventricle is maintained notwithstanding the impaired zone of the myocardium.
  • Such expansion may cause the left ventricle to assume a somewhat spherical shape.
  • Cardiac remodeling often subjects the heart wall to increased wall tension or stress, which further impairs the heart's functional performance. Often, the heart wall will dilate further in order to compensate for the impairment caused by such increased stress. Thus, a vicious cycle can result, in which dilation leads to further dilation and greater functional impairment.
  • congestive heart failure has been managed with a variety of drugs.
  • Devices have also been used to improve cardiac output.
  • left ventricular assist - pumps help the heart to pump blood.
  • Multi-chamber pacing has also been employed to optimally synchronize the beating of the heart chambers to improve cardiac output.
  • Various skeletal muscles such as the latissimus dorsi, have been used to assist ventricular pumping.
  • prosthetic "girdles” disposed around the heart.
  • One such design is a prosthetic "sock” or "jacket” that is wrapped around the heart.
  • a cardiac harness is configured to fit generally around a patient's heart and to resist expansion of the heart by applying a compressive force thereto. At least a section of said harness exerts a circumferential load, normalized with respect to a longitudinal direction and expressed in pounds per inch, as a function of circumferential expansion of said section of harness, expressed as a percent of expansion above a zero load condition.
  • the harness has an operating range of expansion having a minimum value of at least 20 percent. A change of 20 percent in said circumferential expansion within said operating range yields a change in circumferential load of no more than about 0.066 lb/in.
  • a cardiac harness is configured to fit generally around a patient's heart and to resist expansion of the heart by applying a compressive force thereto. At least a section of said harness exerts a circumferential load, normalized with respect to a longitudinal direction and expressed in pounds per inch, as a function of circumferential expansion of said section of harness, expressed as a percent of expansion above a zero load condition.
  • a first value of "a” corresponds to a first selected range of expansion of at least 5 percent
  • a second value of "a” corresponds to a second selected range of expansion of at least 5 percent.
  • the second range of expansion consists of values greater than the first range of expansion so as to be non-overlapping with the first range, and the second value of "a" is no greater than said first value of "a”.
  • the present invention provides a cardiac harness configured to fit generally around a patient's heart and to resist expansion of the heart by applying a compressive force thereto.
  • At least a section of said harness exerts a circumferential load, normalized with respect to a longitudinal direction and expressed in pounds per inch, as a function of circumferential expansion of said section of harness, expressed as a percent of expansion above a zero load condition.
  • the linear regression of said variation of load as a function of expansion yields a coefficient of determination of at least about 0.8.
  • the value of "a” is no greater than about 0.0033. In another embodiment, the value of "a” is no greater than about 0.002.
  • a cardiac harness is configured to fit generally around a patient's heart and to resist expansion of the heart by applying a compressive force thereto. At least a section of said harness exerts a circumferential load, normalized with respect to a longitudinal direction and expressed in pounds per inch, as a function of circumferential expansion of said section of harness, expressed as a percent of expansion above a zero load condition.
  • Figure 1 is a schematic view of a heart with a cardiac harness placed thereon.
  • Figure 2A-2B illustrate a spring hinge in a relaxed position and under tension.
  • Figure 3 shows an embodiment of a cardiac harness that has been cut out of a flat sheet of material.
  • Figure 4 shows the cardiac harness of Figure 3 formed into a shape configured to fit about a heart.
  • Figure 5 shows another embodiment of a cardiac harness that has been cut out of a flat sheet of material.
  • Figure 6 shows the cardiac harness of Figure 5 formed into a shape configured to fit about a heart.
  • Figure 7 is a schematic view of yet another embodiment of a cardiac harness, shown disposed upon a schematically-illustrated heart.
  • Figure 8 illustrates a plurality of strips of material arranged on a patient's heart.
  • Figure 9 illustrates embodiments of an AV groove collar and a papillary muscle band disposed on a patient's heart.
  • Figure 10 shows a curve representing test data for one embodiment of a cardiac harness.
  • Figure 11 shows a test portion which has been cut out of the cardiac harness of Figure 7 generally along line 11-11.
  • Figure 12 shows the test portion of Figure 11 in a material testing machine.
  • Figure 13 shows a curve representing test data for one embodiment of a cardiac harness.
  • Figure 14 shows a schematic view of one typical spring element of a test portion as in Figure 11.
  • Figure 15 shows test data and a linear regression line generated therefrom in accordance with one embodiment of a cardiac harness.
  • Figure 16 shows test data and a linear regression line derived therefrom in connection with another embodiment of the cardiac harness.
  • Figure 17 shows test data and a linear regression line derived therefrom for yet another embodiment of the cardiac harness.
  • Figure 18 shows test data and linear regression line derive therefrom for yet another embodiment of a cardiac harness.
  • Figure 1 illustrates a mammalian heart 30 having a cardiac wall stress reduction device in the form of a harness 32 applied to it.
  • the cardiac harness 32 comprises a series of hinges or spring elements 34 that circumscribe the heart 30 and, collectively, apply a mild compressive force on the heart so as to alleviate wall stresses.
  • cardiac harness is a broad term that refers to a device fit onto a patient's heart to apply a compressive force on the heart during at least a portion of the cardiac cycle.
  • Other devices that are intended to be fit onto a heart and are referred to in the art as “girdles,” “socks,” “jackets,” or the like are included within the meaning of "cardiac harness.”
  • the cardiac harness 32 illustrated in Figure 1 comprises at least one undulating strand 36 comprising a series of spring elements 34 referred to as hinges or spring hinges that are configured to deform as the heart 30 expands during filling.
  • Each hinge 34 provides substantially unidirectional elasticity, in that it acts in one direction and does not provide much elasticity in the direction perpendicular to that direction.
  • Figure 2A shows one embodiment of a hinge member 34 at rest.
  • the hinge member 34 has a central portion 40 and a pair of arms 42. As the arms are pulled, as shown in Figure 2B, a bending moment 44 is imposed on the central portion 40. The bending moment 44 urges the hinge member 34 back to its relaxed condition.
  • a typical strand comprises a series of such hinges, and that the hinges 34 are adapted to elastically expand and retract in the direction of the strand 36.
  • the strands 36 of spring elements 34 are constructed of extruded wire that is deformed to form the spring elements.
  • FIGS 3 and 4 illustrate another preferred embodiment of a cardiac harness 50, shown at two points during manufacture of such a harness.
  • the harness 50 is first formed from a relatively thin, flat sheet of material. Any method can be used to force the harness from the flat sheet.
  • the harness is photochemically etched from the material; in another embodiment, the harness is laser-cut from the thin sheet of material.
  • the embodiment shown in Figures 3 and 4 has been etched from a thin sheet of Nitinol, which is a superelastic material that also exhibits shape memory properties.
  • the illustrated embodiments of the cardiac harnesses 32, 50 comprise a base portion 52, which is sized and configured to generally engage and fit onto a base region of a patient's heart; an apex portion 56, which is sized and shaped so as to generally engage and fit on an apex region of a patient's heart; and a medial portion 58 between the base and apex portions.
  • the harness 50 comprises strands or rows 36 of undulating wire.
  • the undulations comprise hinges/spring elements 34 which are elastically bendable in a desired direction.
  • Some of the strands 36 are connected to each other by interconnecting elements 60.
  • the interconnecting elements 60 help maintain the position of the strands 36 relative to one another.
  • the interconnecting elements 60 allow some relative movement between adjacent strands 36.
  • the undulating spring elements 34 exert a force in resistance to expansion of the heart 30.
  • the force exerted by the spring elements tends toward compressing the heart, thus alleviating wall stresses in the heart as the heart expands.
  • Each strand of spring hinges is configured so that as the heart expands during diastole the spring hinges correspondingly expand, storing expansion forces as bending energy in the spring. As such, the stress load on the myocardium is partially relieved by the harness. This reduction in stress helps to decrease the workload of the heart, enabling the heart to ⁇ more effectively pump blood and helping the myocardium cells to remain healthy and/or regain health.
  • cardiac harnesses can be constructed and that such embodiments may have varying configurations, sizes, flexibilities, etc. yet still create a mildly compressive force on the heart so as to reduce wall stresses.
  • cardiac harnesses can be constructed from many suitable materials including various metals, fabrics, plastics and braided, woven and/or knit filaments. Suitable materials also include superelastic materials and materials that exhibit shape memory.
  • a preferred embodiment of a harness is constructed of Nitinol. Shape memory polymers can also be employed.
  • Such shape memory polymers can include shape memory polyurethanes or other polymers such as those containing oligo(e- caprolactone) dimethacrylate and/or poly(e-caprolactone), which are available from mnemoScience.
  • some cardiac harness embodiments substantially encircle the heart, while others may employ spring members disposed over only a portion of the circumference of the heart or harness. As just discussed, bending stresses are absorbed by the spring members 34 during diastole and are stored in the members as bending energy. During systole, when the heart pumps, the heart muscles contract and the heart becomes smaller.
  • a harness 50 comprises strands 36 or strips of undulating wire.
  • the undulations comprise hinges/spring elements 34 which are elastically bendable in a desired direction.
  • the strands of spring elements are oriented in different directions and configured differently in the various portions of the harness.
  • the strands are oriented so that the spring elements 34 will expand and contract in a direction generally transverse to a longitudinal axis of the heart.
  • an "archimedes spiral" 62 configuration allows expansion and deformation in more than one direction, but is most compliant in a longitudinal direction.
  • strands 36a are oriented to expand and contract in a generally longitudinal direction. Additionally, some of the strands are connected to each other by interconnecting spring elements 60a, which allow the adjacent strands to move relative to each other in a transverse direction.
  • the strands 36a in the medial portion 58 are not connected to others of the strands and can move freely relative to one another in a transverse direction.
  • the strands are collectively expandable in directions between the longitudinal and transverse directions.
  • the heart muscle cells in the base region tend to expand and contract in a generally transverse direction during pumping of the heart.
  • the heart muscles tend to expand and contract in a longitudinal direction.
  • the heart muscles generally expand and contract in directions between the longitudinal and transverse directions.
  • the spring elements 34 are oriented generally in the directions of the cardiac muscle expansion so as to even better resist expansion and alleviate muscle stresses.
  • the arrangement of the base, medial and apex regions 52, 58, 56 of the harness is specially adapted to accommodate the natural expansion and contraction of heart muscle tissue.
  • the harness generally mimics the directional contractions typical of heart muscle.
  • FIG. 7 another embodiment of a cardiac harness 70 is illustrated disposed on a schematically illustrated heart 30. As shown, the cardiac harness 70 is configured to circumferentially surround the heart and extend longitudinally from a base portion 72 to an apex portion 74 of the heart.
  • the harness 70 comprises a plurality of circumferentially extending rings 80 disposed longitudinally adjacent to one another.
  • Each ring 80 comprises a plurality of interconnected spring members 34.
  • the spring members 34 shown in Figure 7 are substantially similar to the spring members 34 discussed above with reference to Figures 2 A and 2B.
  • a plurality of connectors 82 interconnects adjacent rings 80.
  • the connectors 82 have a length oriented longitudinally relative to the rings so as to create space between adjacent rings. Further, the connectors help to maintain proper alignment between adjacent rings, while allowing some relative movement therebetween.
  • the illustrated harness is configured so that no spring members 34 overlap one another. As such, wear of the harness due to repeated flexing and relative movement of the spring members 34 is avoided.
  • each ring 80 initially comprises an elongate strand comprised of a series of spring members 34.
  • Each strand of spring members 34 preferably is formed of a drawn metallic wire, preferably Nitinol or another metal having a shape memory property.
  • the Nitinol wire is shaped into the series of spring members and treated to develop a shape memory of the desired spring member structure.
  • each elongate strand is cut to a length such that when opposite ends of the elongate strand are connected, the elongate strand assumes the ring-shaped configuration shown in Figure 7.
  • the lengths of the elongate strands 36 are selected such that the resulting rings 80 are sized in conformity with the general anatomy of the patient's heart 30. More specifically, strands used in the apex portion of the harness are not as long as the strands used to form the base portion. As such, the harness generally tapers from the base 52 toward the apex 54 in order to generally follow the shape of the patient's heart.
  • the diameter of a ring 80b at the base of the harness is smaller than the diameter of the adjacent ring 80c.
  • the harness has a greatest diameter at a point between the base and apex ends, and tapers from that point to both the base and apex ends.
  • the point of greatest diameter is closer to the base end 52 than to the apex end 56.
  • the lengths of the strands, as well as the sizes of the spring members, may be selected according to the intended size of the cardiac harness 70 and/or the amount of compressive force the harness is intended to impart to the patient's heart.
  • the right side 84 of the base portion 52 of the harness 70 comprises strands 86 of interconnected spring members that are not configured into a ring, but extend only partially about the circumference of the harness 80.
  • the partial strands 86 are connected to the adjacent full ring in a manner so that the partial strands are stretched. As such, the partial strands 86 will bend inwardly to "cup" the upper portion of the right atrium, as simulated in Figure 7.
  • the rings 80 are coated with dielectric material and the connectors 82 are formed of a nonconductive material. As such, each ring is electrically isolated from the other rings in the harness.
  • silicone tubing is advanced over a strand of spring members prior to forming the strand into a ring.
  • Nitinol wire is dip coated with an insulating material before or after being formed into rings.
  • Various materials and methods can be used to coat the harness with dielectric material.
  • the rings are coated with silicone rubber.
  • Other acceptable materials include urethanes and ceramics, as well as various polymers and the like, including ParyleneTM, a dielectric polymer available from Union Carbide.
  • the materials can be applied to a harness by various methods, such as dip coating and spraying, or any other suitable method.
  • adjacent rings 80 are joined to one another by connectors 82.
  • connectors 82 are generally staggered between adjacent rings 80. It is to be understood that, in other embodiments, different arrangements of connectors 82 can be employed.
  • connectors between adjacent rings can be substantially aligned with one another.
  • the connectors 82 comprise silicone rubber.
  • the connectors are somewhat elastic, and the harness 70 is longitudinally compliant.
  • the longitudinal compliance of the harness is limited by the elastic properties of the connectors. Due to both the geometry of the rings and elastic properties of the ring material, the circumferential compliance of the harness 70 is much greater than the longitudinal compliance.
  • the longitudinal compliance of the harness is even more closely limited by the elastic properties of the connectors, and such an embodiment would be less longitudinally compliant than the embodiment of Figure 7.
  • a harness is constructed of polyester filaments knit in a well known "Atlas knit" arrangement, such as that discussed in international patent Publication Number WO 01/95830 A2, which is incorporated herein by reference in its entirety.
  • the harness is flexible, and the fabric can stretch, even though the polyester filaments do not necessarily elastically deform upon stretching of the fabric.
  • Such fabric stretch is mainly due to linearization of filaments and fiber crimp and geometric distortion of the knit pattern.
  • the harness becomes inelastic, and will no longer expand elastically with an increase in size of a patient's heart.
  • tissue On or around the foreign object.
  • fibrin and collagen deposits will tend to accumulate on and around the heart after a cardiac harness is placed thereon. This scar tissue tends to be tough, though flexible, and will additionally resist expansion of the patient's heart.
  • a cardiac wall tension reduction device is constructed of a bioabsorbable material. As such, the device will dissolve after a predetermined period of time. When in place, however, the device will relieve cardiac wall tension.
  • the patient's body will respond by depositing scar tissue on the device and around the heart. Preferably, the tissue at least partially encapsulates the heart. After the device dissolves, the scar tissue remains. Thus, although the implanted device no longer restricts or resists further cardiac expansion, the scar tissue resists such expansion. As such, a long term treatment for resisting further cardiac expansion is established without requiring a permanent implant.
  • a bioabsorbable cardiac wall tension reduction device can be formed of any bioabsorbable material.
  • bioabsorbable materials include materials that degrade or dissolve over time when placed within a human body, and include biodegradable materials.
  • FDA-approved materials such as polylactic acid (PLA) and polyglycolic acid
  • PGA PGA
  • Other materials, including both synthetic and naturally-derived polymers can suitably be employed.
  • a bioabsorbable cardiac harness can be formed in accordance with any acceptable method and fashion.
  • a sheet of PGA or PLA can be molded to a shape that fits about the heart.
  • a sheet can be formed having holes or gaps that lend themselves to increased flexibility.
  • a device can be molded or cut to have a series of undulating spring members, as in the embodiments discussed above.
  • a lattice structure may be used to provide elasticity and facilitate and/or direct scar growth in a desired manner and direction.
  • bioabsorbable material can be provided as extruded fibers or filaments that can be woven, braided, knit, or the like so as to fit about the heart and constrain expansion thereof.
  • bioabsorbable material can be provided as extruded fibers or filaments that can be woven, braided, knit, or the like so as to fit about the heart and constrain expansion thereof.
  • a cardiac wall tension reduction device is at least partially made of a bioabsorbable material that is combined with medically-beneficial medicaments so that the beneficial medicaments are released as the bioabsorbable material dissolves.
  • a bioabsorbable material for example, bone marrow or stem cells can be provided so as to possibly stimulate myocardial regeneration. This type of treatment may help resolve an infarct, and promote healing of the heart.
  • a bioabsorbable cardiac harness can be combined with anti- fibrin drugs and/or other medications that resist the deposit or growth of body tissues around the installed harness.
  • the harness reduces heart wall stresses, giving the heart an opportunity to begin healing, but will not form extensive scar tissue.
  • the harness is adapted so that it will dissolve after a period of time sufficient to rest the heart so that it can continue its work without developing worsening symptoms of disease. Since little or no scar tissue is left behind after the harness dissolves, the rested heart will not be restricted by such tissue. Although, as discussed above, scar tissue can sometimes serve a beneficial purpose, some situations benefit from avoidance of scar tissue.
  • the heart will reverse remodel when a harness reduces cardiac wall stress. As such, the heart may be smaller when a bioabsorbable harness dissolves than when the harness was installed.
  • a new, smaller harness is then to be placed on the heart, thus prompting further reverse remodeling. This process can be repeated as often as desired, until the heart has reached a desired size and health level.
  • further harnesses may not be needed because the heart is healthy enough to maintain its size.
  • a permanent harness may be installed to maintain the heart at the desired size.
  • another bioabsorbable harness is installed, but without anti-tissue-growth drugs. As such, the heart becomes at least partially encapsulated in body tissues that will resist enlargement of the heart beyond the desired size. This helps the heart maintain the desired healthy size.
  • foreign bodies are introduced about the heart so as to stimulate tissue growth that will at least partially encapsulate the heart.
  • These foreign bodies need not be in the form of a cardiac harness, and need not impart any compressive force on the heart.
  • these foreign bodies will stimulate fibrin/collagen or other tissue growth about the heart so as to at least partially encapsulate the heart in the tissue.
  • the tissue will act as a sock or jacket to resist further expansion of the heart.
  • the foreign matter can be bioabsorbable, but is not necessarily so.
  • the foreign matter can comprise a liquid or powder irritant specially adapted to stimulate fibrin or collagen growth.
  • Such irritants may include shredded or powderized polyester or other plastics.
  • foreign matter or a cardiac harness can be arranged around the heart so as to stimulate tissue growth at specified locations and in desired directions.
  • matter can be placed so as to stimulate tissue growth in a configuration that generally follows the directional expansion and contraction of heart muscle.
  • foreign material is arranged on or around the heart 30 in a series of strips 90 which are arranged to generally correspond to the directional expansion and contraction of heart muscle. This prompts tissue growth in the area and directional configuration of the strips 90. As such, the tissue grows to generally correspond to the directional expansion and contraction of heart muscle. Such tissue will help reduce the muscle load as the heart expands during filling and contracts during pumping.
  • the foreign matter that stimulates the tissue growth comprises a bioabsorbable material.
  • the foreign matter is not bioabsorbable and is maintained permanently in the patient's body.
  • Introduction and placement of foreign material around the patient's heart can be performed via minimally-invasive methods.
  • Minimally invasive methods can also be used to install a Nitinol, woven and/or bioabsorbable harness around the heart.
  • Even less invasive methods can be used to place loose or detached foreign matter about the heart.
  • the armulus of certain valves, such as the mural valve tends to grow with the heart.
  • the valve a mulus may increase in size to a point at which the leaflets are not large enough to completely close the valve.
  • valve dysfunction Another factor contributing to valve dysfunction is that as the heart enlarges, the geometry of the heart changes somewhat. Portions of the heart, such as the papillary muscles, are moved outwardly from the leaflets to which the papillary, muscles are attached via the chordae tendinaea. These papillary muscles may be stretched so much that they prevent the valve leaflets from adequately engaging each other during valve closure. As such, the leaflets will not be able to fully close, and the valve will leak. Such valve leakage simply makes the patient's heart problems worse. As discussed in the above-referenced application entitled "Heart Failure Treatment
  • a harness or collar can be configured to exert a compressive force on specific portions of a heart so as to help prevent or diminish valve dysfunction.
  • a collar-type device can be specially configured to fit around the AV groove region 92 of the heart 30.
  • Figure 9 shows an AV groove collar 94 arranged and configured to exert a compressive force that will tend to decrease the size of the valvular annuli and/or prevent enlargement of the valvular annuli beyond desired sizes.
  • a papillary muscle band 96 can be configured to be placed around the outside of the heart 30 in the area of the papillary muscles. As l ⁇ iown in the art, the papillary muscles are generally midway between the AV groove and the apex of the heart.
  • a papillary muscle band 96 can exert a compressive force to reduce the diameter of the heart at the level of the papillary muscles. This will help the papillary muscles become less stretched so that they allow and facilitate closure of the valve leaflets.
  • the papillary band 96 is constructed of a woven or knit fabric. It is to be understood that the papillary band 96 can also have an undulating spring hinge construction such as that shown and discussed in connection with the embodiments presented in FIGURES 1-7.
  • the AV groove collar 94 and/or papillary muscle band 96 can be constructed of a substantially elastic material, such as silicone rubber. As discussed above, a cardiac harness applies a mild compressive force on a patient's heart.
  • an AV groove collar 94 and papillary muscle band 96 will exert a more aggressive compressive force than a typical cardiac harness.
  • a permanent cardiac harness implant is coated with an irritant in the portions configured to engage the AV groove 92 and/or papillary muscle regions of the heart so as to provide a more dramatic stimulus for tissue growth in these portions.
  • tissue growth in the AV groove and papillary muscle areas of the heart will be increased, providing further resistance to expansion in these areas.
  • a bioabsorbable woven or knit AV groove collar 94 stimulates tissue growth in and around the AV groove so as to provide similar benefits without a permanent implant.
  • a bioabsorbable papillary muscle band 96 is similarly provided.
  • the AV groove collar 94 and papillary muscle band 96 can be used independent of one another or in conjunction with one another and either independent of or in conjunction with a permanent or bioabsorbable cardiac harness.
  • a papillary muscle band can be placed on the heart before or after installation of a cardiac harness.
  • an AV groove collar 94 and papillary band 96 can be incorporated into a cardiac harness so as to apply specially-directed forces to the specific portions of the heart and to create specific regions of increased tissue growth.
  • an AV groove collar and/or papillary band is constructed of a bioabsorbable material and is configured to exert a force on a patient's heart within a first force range.
  • a cardiac harness is provided and is configured to exert a force on the patient's heart within a second force range.
  • the first range of force which is to be exerted by the papillary band or AV groove collar, induces generally greater levels of force than the second range.
  • a greater force is exerted at the AV groove or papillary band region of the heart than elsewhere.
  • the applied force on the heart becomes more equalized.
  • the AV groove collar and/or papillary muscle band is formed from a bioabsorbable material and is configured to have a maximum dimension beyond which the collar/band will not deform. As such, a selected portion of the heart can be constrained to a specific size while the rest of the heart is not so constrained. This enables passive treatment of the heart as a whole while also addressing an acute issue.
  • a bioabsorbable member can temporarily apply a targeted, increased force in a desired portion of the patient's heart while an accompanying cardiac harness provides a more even, mild and permanent compressive force over a larger portion of the heart.
  • the cardiac harness preferably applies a mild compressive force on the heart in order to achieve therapeutic benefits.
  • An applied force or pressure within a therapeutic range is defined herein as a pressure of sufficient magnitude that, when applied to an organ such as the heart, results in a benefit to the organ.
  • the therapeutic range for a cardiac harness is between about 2-20 mmHg. More preferably, the therapeutic pressure is about 2-10 mmHg, and most preferably is between about 2-5 mmHg.
  • a pressure versus percentage tensile strain curve 100 is presented reflecting actual test data for one embodiment of a cardiac harness constructed of drawn Nitinol wire formed into undulating spring hinges.
  • this harness embodiment is capable of extensive deformation.
  • the harness is stretched from its original, at-rest position in order to be fit over the patient's heart.
  • it applies a mild, compressive force, which will tend to help the heart reverse-remodel.
  • the harness correspondingly becomes smaller.
  • the size of the heart varies between the beginning of diastole and the end of diastole.
  • the labels Ds and D F have been applied to the curve to identify the pressure applied by the harness at a particular level of tensile strain ⁇ corresponding to the beginning Ds and end Dp of diastole.
  • the labels D's, and D illustrate the relative pressures applied by the harness at the beginning and end of diastole as the heart reverse remodels and becomes smaller.
  • the cardiac harness adjusts continuously with the heart as the heart changes in size, and also applies a therapeutic pressure to the heart even when the heart reverse remodels extensively.
  • the cardiac harness exerts a pressure in response to strain of the harness. For example, if the harness is strained about 100%, it will exert about lOmmHg on the heart.
  • the harness is configured so that the applied pressure varies relatively little over a broad range of deformation.
  • the harness provides a therapeutic pressure even after the heart has reverse remodeled extensively.
  • a reduction in size corresponding to a 40%) change in strain as the harness reduces from 100% to 60% strain is accompanied by a decrease in applied pressure of less than about 3mmHg.
  • a 40% change from 80% to 40% strain is accompanied by a decrease in applied pressure of less than about 4mmHg.
  • a 20% reduction in size can be accompanied by a decrease in applied pressure of less than about 3mmHg or, depending on the degree of strain of the harness, less than about 2mmHg. Additional relationships indicating changes in applied pressure corresponding to changes in the size/strain of the harness can be derived from the illustrated pressure/strain curve of Figure 10.
  • Figure 10 is coated with a bioabsorbable coating including a medicament that inhibits growth of tissue in response to introduction of a foreign body.
  • a bioabsorbable coating including a medicament that inhibits growth of tissue in response to introduction of a foreign body.
  • scar tissue growth around the heart and harness will be minimized, and the harness can dramatically decrease in size as the heart reverse remodels without scar tissue preventing the harness from adjusting and changing shape with the patient's heart.
  • Figure 11 shows an elongate test portion 110 that is taken from a cardiac harness.
  • the test portion 110 has been taken from the harness 70 of Figure 7 generally along the lines 11-11.
  • test portion 110 preferably has a length L and a width W.
  • the length L is defined in a direction generally along the circumference of the harness. In other words, the length L is taken in a direction generally transverse to a longitudinal axis of the heart and harness. Most preferably, the length L is taken in the direction generally perpendicular to the longitudinal axis.
  • the width W extends in a direction generally along the longitudinal axis.
  • the test portion 110 preferably is placed in a material property testing machine 112 such as is available from InstronTM.
  • the test portion 110 of the harness preferably is disposed in mounts 114 of the materials testing machine 112, and the machine pulls the test portion 110 along its length L.
  • the materials testing machine 112 collects data detailing the load, in pounds force (lbF), and the corresponding percent tensile strain of the test portion 110 along the length L.
  • the load is then normalized with reference to the width W of the test portion which, in the illustrated embodiment, is in a longitudinal direction.
  • load data is taken in the units of
  • test procedure allows measurement of the elasticity/deformation behavior of various embodiments of cardiac harnesses so that such embodiments can be compared.
  • testing preferably is performed at room temperature, preferably about 37° C.
  • the load is applied along the length L of the test portion
  • the applied load represents and corresponds to a circumferential load of the harness.
  • the percent tensile strain is also taken along the length L.
  • the percent tensile strain represents and corresponds to a percent of circumferential expansion of the harness above a zero load condition.
  • Figure 13 an anticipated compliance curve charting the compliance of one embodiment of a cardiac harness is presented.
  • the illustrated graph represents behavior of a cardiac harness constructed of a knit material such as a harness constructed employing an "atlas knit" as discussed above.
  • the tested embodiment appears generally parabolic in shape. That is, as the percent tensile strain increases the corresponding load increases exponentially.
  • an asymptote will be defined at a percent strain between about 40%-50%. At that point the test portion will have reached its limit of expansion.
  • an exemplary spring element 34 of a harness such as the harness 70 of Figure 7 is illustrated.
  • the spring element 34 of Figure 14 represents one element from a strand of such spring elements. This figure will be used to define the dimensions of some specific embodiments for which test data has been obtained.
  • plotted test data is presented for a test portion of a cardiac harness.
  • the cardiac harness exemplified by the test data of Figure 15 comprises strands of spring elements preferably formed of drawn Nitinol wire having a diameter of about 0.008 in.
  • the spring elements resemble the spring element 34 shown in Figure 14, and have a width w of about 0.165 in., a height h of about 0.163 in., and a diameter ⁇ of about 0.126 in.
  • the wire is formed into strands of spring elements, it is heat treated at about 485° C for about 30 minutes. Silicone tubing having an inner diameter of about 0.010 in. and an outer diameter of about 0.025 in. is disposed over the strand.
  • a test portion of the just-described cardiac harness was tested in a materials testing machine in accordance with the procedure discussed above. Test data, including load and percent tensile strain, was collected between a zero load, zero percent strain condition and about a 100% strain condition. Representative test data points are set out in the plot of Figure
  • the cardiac harness exemplified by the test data of Figure 16 comprises strands of spring elements preferably formed of drawn Nitinol wire having a diameter of about 0.012 in.
  • the spring elements resemble the spring element 34 shown in Figure 14, and have a width w of about 0.300 in., a height h of about 0.275 in., and a diameter ⁇ of about 0.250 in.
  • the wire is heat treated at about 485° C for about 30 minutes. Silicone tubing having an inner diameter of about 0.014 in.
  • test data including load and percent tensile strain, was collected between a zero load, zero percent strain condition and about a 100% strain condition. Representative test data points are set out in the plot of Figure
  • the cardiac harness exemplified by the test data of Figure 17 comprises strands of spring elements preferably formed of drawn Nitinol wire having a diameter of about 0.012 in.
  • the spring elements resemble the spring element 34 shown in Figure 14, and have a width w of about 0.300 in., a height h of about 0.275 in., and a diameter ⁇ of about 0.250 in.
  • the wire is heat treated at about 485° C for about 30 minutes. Silicone tubing having an inner diameter of about 0.014 in. and an outer diameter of about 0.029 in. is disposed over the strand.
  • the cardiac harness represented in Figure 17 is structurally very similar to the cardiac harness represented in Figure 16.
  • the linear regression function has a coefficient of determination R 2 of about 0.9933.
  • plotted test data is presented for a test portion of another embodiment of a cardiac harness.
  • the cardiac harness exemplified by the test data of Figure 18 comprises strands of spring elements preferably formed of drawn Nitinol wire having a diameter of about 0.011 in.
  • the spring elements resemble the spring element 34 shown in Figure 14, and have a width w of about 0.165 in., a height h of about 0.163 in., and a diameter ⁇ of about 0.126 in.
  • the wire is formed into strands of spring elements, it is heat treated at about 485° C for about 30 minutes. Silicone tubing is disposed over the strand.
  • a test portion of the just-described cardiac harness was tested in a materials testing machine in accordance with the procedure discussed above. Test data, including load and percent tensile strain, was collected between a zero load, zero percent strain condition and about a 100% strain condition.
  • test data points are set out in the plot of Figure 18, in which percent strain is plotted along the x axis, and load, normalized with respect to the width W of the test portion, is plotted along the y axis.
  • the linear regression function has a coefficient of determination R 2 of about 0.9749.
  • a cardiac harness comprises strands of spring elements formed of drawn Nitinol wire having a diameter of about 0.016 in.
  • the spring elements resemble the spring element shown in Figure 14, and have a width w of about 0.289 in., a height h of about 0.275 in., and a diameter ⁇ of about 0.250 in.
  • the wire is formed into strands of spring elements, it is heat treated at about 515° C for about 25 minutes. Silicone tubing is disposed over the strand.
  • a test portion of the just-described cardiac harness was tested in a materials testing machine in accordance with the procedure discussed above.
  • Test data including load and percent tensile strain, was collected between a zero load, zero percent strain condition and about a 100% strain condition.
  • the linear regression function has a coefficient of determination R 2 of about 0.9945.
  • the tested range of expansion of about 0-100%) represents a proposed operating range of expansion for each harness.
  • the compliance behavior of the harness embodiments is known and predictable.
  • the cardiac harness is sized and configured relative to a patient's heart so that the operating range of the harness is up to about 75% expansion.
  • the operating range of the harness is up to about 50% expansion.
  • an operating range of the harness should be taken to mean a range over which the compliance behavior of the harness is acceptable for its intended purpose of providing a mild compressive force to the patient's heart without defining a limit beyond which the heart cannot expand.
  • the compliance behavior of the associated harnesses can be predicted over any range of expansion or load. For example, with reference to the embodiment of Figure 18, it can be determined that a change of about 20 percent in circumferential expansion within an operating range of expansion having a minimum value of at least 20 percent yields a change in circumferential load of about 0.066 lb/in.
  • a change of about 20 percent in circumferential expansion within an operating range of expansion between about 0 and 100 percent yields a change in circumferential load of about 0.02 lb/in.
  • Experimental studies indicate that a cardiac harness having compliance properties as in the embodiment of Figure 15 provide a beneficial therapeutic effect to a diseased heart.
  • studies also indicate that a cardiac harness having compliance properties as in the embodiment of Figure 18 also provides a beneficial therapeutic effect.
  • a cardiac harness has compliance properties at or more compliant than the embodiment of Figure 18.
  • a change of about 20 percent in circumferential expansion yields a change in circumferential load no greater than about 0.066 lb/in.
  • the constant "a” represents the slope of the function.
  • the slope of the test data declines as the percent expansion increases.
  • a first slope "a” is calculated by linear regression over a first selected range of expansion
  • a second slope "a” is calculated over a second selected range of expansion, which second range consists of expansion values greater than the first range
  • the second slope "a" will be less than the first slope "a”.
  • the second slope "a” will be nearly the same as, but no greater than the first slope "a” for at least portions of the test data.
  • each of the first and second ranges of data comprise a significant range of data, such as over at least five percent of expansion.
  • the second slope "a" is no greater than the first slope "a”. It is further helpful to analyze such behavior over only portions of the range of expansion that are expected to be used during operation of the harness.
  • the second slope "a" is no greater than the first slope "a" within an operational range of expansion of the harness of about 0-100 percent expansion.
  • the first selected range of expansion is within a range between about 20 and 30 percent expansion
  • the second selected range of expansion is within a range between about 25 and 100 percent expansion.
  • the second selected range of expansion is within a range between about 25 and 50 percent expansion.
  • the compliance function has been defined by linear regression of test data taken over a percent expansion between about 0-100%>. It is to be understood that such an analysis may also be helpful if taken over a more limited range of percent expansion.
  • the operating range of the harness may, in some embodiments, be limited to such a range of expansion.
  • the coefficients of determination have been very close to 1. More particularly, the coefficients of determination are greater than about 0.9 band, in some embodiments, greater than about 0.98.
  • a compliance function determined by linear regression has a coefficient of determination of at least about 0.8 in order to be helpful for analysis as discussed herein. For each of the analyses discussed above, characteristics over certain exemplary ranges of expansion have been specifically discussed.

Abstract

A cardiac harness for treating or preventing congestive heart failure is configured to be placed about at least a portion of a patient’s heart so as to apply a mild compressive force on the heart. In one embodiment, the cardiac harness is configured so that the variation of load as a function of expansion through a selected range of expansion is represented generally in the form y=ax+b, and the value of “a” does not increase as the percent expansion increases.

Description

CARDIAC HARNESS CROSS-REFERENCES TO RELATED APPLICATIONS This application is a continuation in part of U.S. Patent Application No. 10/338,934, which was filed on January 7, 2003, and which is based on and claims priority to U.S. Provisional Application No. 60/346,788, filed January 7, 2002. The entirety of both of these applications are hereby incorporated by reference.
BACKGROUND OF THE INVENTION FIELD OF THE INVENTION The present invention relates to a device for treating heart failure. More specifically, the invention relates to a cardiac harness configured to be fit around at least a portion of a patient's heart. DESCRIPTION OF THE RELATED ART Congestive heart failure ("CHF") is characterized by the failure of the heart to pump blood at sufficient flow rates to meet the metabolic demand of tissues, especially the demand for oxygen. One characteristic of CHF is remodeling of at least portions of a patient's heart. Remodeling involves physical changes to the size, shape and thickness of the heart wall. For example, a damaged left ventricle may have some localized thinning and stretching of a portion of the myocardium. The thinned portion of the myocardium often is functionally impaired, and other portions of the myocardium attempt to compensate. As a result, the other portions of the myocardium may expand so that the stroke volume of the ventricle is maintained notwithstanding the impaired zone of the myocardium. Such expansion may cause the left ventricle to assume a somewhat spherical shape. Cardiac remodeling often subjects the heart wall to increased wall tension or stress, which further impairs the heart's functional performance. Often, the heart wall will dilate further in order to compensate for the impairment caused by such increased stress. Thus, a vicious cycle can result, in which dilation leads to further dilation and greater functional impairment. Historically, congestive heart failure has been managed with a variety of drugs. Devices have also been used to improve cardiac output. For example, left ventricular assist - pumps help the heart to pump blood. Multi-chamber pacing has also been employed to optimally synchronize the beating of the heart chambers to improve cardiac output. Various skeletal muscles, such as the latissimus dorsi, have been used to assist ventricular pumping. Researchers and cardiac surgeons have also experimented with prosthetic "girdles" disposed around the heart. One such design is a prosthetic "sock" or "jacket" that is wrapped around the heart. Although some of the above-discussed devices hold promise, there remains a need in the art for an improved device for treating CHF to prevent a remodeled heart from further remodeling and/or help reverse remodeling of a diseased heart.
SUMMARY OF THE INVENTION In accordance with one embodiment of the present invention, a cardiac harness is configured to fit generally around a patient's heart and to resist expansion of the heart by applying a compressive force thereto. At least a section of said harness exerts a circumferential load, normalized with respect to a longitudinal direction and expressed in pounds per inch, as a function of circumferential expansion of said section of harness, expressed as a percent of expansion above a zero load condition. The harness has an operating range of expansion having a minimum value of at least 20 percent. A change of 20 percent in said circumferential expansion within said operating range yields a change in circumferential load of no more than about 0.066 lb/in. In accordance with a further embodiment, the circumferential compliance of the harness over the operating range of expansion is greater than a longitudinal compliance of the harness. In accordance with another embodiment of the present invention, a cardiac harness is configured to fit generally around a patient's heart and to resist expansion of the heart by applying a compressive force thereto. At least a section of said harness exerts a circumferential load, normalized with respect to a longitudinal direction and expressed in pounds per inch, as a function of circumferential expansion of said section of harness, expressed as a percent of expansion above a zero load condition. The variation of load as a function of expansion through a selected range of expansion is generally in the form of y=ax+b where a and b are determined by linear regression. A first value of "a" corresponds to a first selected range of expansion of at least 5 percent, and a second value of "a" corresponds to a second selected range of expansion of at least 5 percent. The second range of expansion consists of values greater than the first range of expansion so as to be non-overlapping with the first range, and the second value of "a" is no greater than said first value of "a". In accordance with another embodiment, the present invention provides a cardiac harness configured to fit generally around a patient's heart and to resist expansion of the heart by applying a compressive force thereto. At least a section of said harness exerts a circumferential load, normalized with respect to a longitudinal direction and expressed in pounds per inch, as a function of circumferential expansion of said section of harness, expressed as a percent of expansion above a zero load condition. The variation of load as a function of expansion between 20 percent expansion and 30 percent expansion is generally in the form of y=ax+b where "a" and "b" are determined by linear regression. The linear regression of said variation of load as a function of expansion yields a coefficient of determination of at least about 0.8. The value of "a" is no greater than about 0.0033. In another embodiment, the value of "a" is no greater than about 0.002. In accordance with still a further embodiment of the present invention, a cardiac harness is configured to fit generally around a patient's heart and to resist expansion of the heart by applying a compressive force thereto. At least a section of said harness exerts a circumferential load, normalized with respect to a longitudinal direction and expressed in pounds per inch, as a function of circumferential expansion of said section of harness, expressed as a percent of expansion above a zero load condition. The variation of load as a function of expansion through a selected range of expansion is generally in the form of y=cx2+ax+b where c, a and b are determined by linear regression, and c is negative. Further features and advantages of the present invention will become apparent to one of skill in the art in view of the Detailed Description of Preferred Embodiments which follows, when considered together with the attached drawings and claims.
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a schematic view of a heart with a cardiac harness placed thereon. Figure 2A-2B illustrate a spring hinge in a relaxed position and under tension. Figure 3 shows an embodiment of a cardiac harness that has been cut out of a flat sheet of material. Figure 4 shows the cardiac harness of Figure 3 formed into a shape configured to fit about a heart. Figure 5 shows another embodiment of a cardiac harness that has been cut out of a flat sheet of material. Figure 6 shows the cardiac harness of Figure 5 formed into a shape configured to fit about a heart. Figure 7 is a schematic view of yet another embodiment of a cardiac harness, shown disposed upon a schematically-illustrated heart. Figure 8 illustrates a plurality of strips of material arranged on a patient's heart. Figure 9 illustrates embodiments of an AV groove collar and a papillary muscle band disposed on a patient's heart. Figure 10 shows a curve representing test data for one embodiment of a cardiac harness. Figure 11 shows a test portion which has been cut out of the cardiac harness of Figure 7 generally along line 11-11. Figure 12 shows the test portion of Figure 11 in a material testing machine. Figure 13 shows a curve representing test data for one embodiment of a cardiac harness. Figure 14 shows a schematic view of one typical spring element of a test portion as in Figure 11. Figure 15 shows test data and a linear regression line generated therefrom in accordance with one embodiment of a cardiac harness. Figure 16 shows test data and a linear regression line derived therefrom in connection with another embodiment of the cardiac harness. Figure 17 shows test data and a linear regression line derived therefrom for yet another embodiment of the cardiac harness. Figure 18 shows test data and linear regression line derive therefrom for yet another embodiment of a cardiac harness.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS This application relates to a method and apparatus for treating heart failure. As discussed in Applicants' co-pending application entitled "Expandable Cardiac Harness For Treating Congestive Heart Failure", Serial No. 09/634,043, which was filed on August 8, 2000, the entirety of which is hereby expressly incorporated by reference herein, it is anticipated that remodeling of a diseased heart can be resisted or even reversed by alleviating the wall stresses in such a heart. The present application discusses certain embodiments and methods for supporting the cardiac wall. Additional embodiments and aspects are also discussed in Applicants' co-pending applications entitled "Cardiac Harness," Serial No. 10/656,733, filed September 5, 2003, "Device for Treating Heart Failure," Serial No. 10/242,016, filed September 10, 2002, and "Heart Failure Treatment Device and Method", Serial No. 10/287,723, filed October 31, 2002, the entirety of each of which are hereby expressly incorporated by reference. Figure 1 illustrates a mammalian heart 30 having a cardiac wall stress reduction device in the form of a harness 32 applied to it. The cardiac harness 32 comprises a series of hinges or spring elements 34 that circumscribe the heart 30 and, collectively, apply a mild compressive force on the heart so as to alleviate wall stresses. The term "cardiac harness" as used herein is a broad term that refers to a device fit onto a patient's heart to apply a compressive force on the heart during at least a portion of the cardiac cycle. Other devices that are intended to be fit onto a heart and are referred to in the art as "girdles," "socks," "jackets," or the like are included within the meaning of "cardiac harness." The cardiac harness 32 illustrated in Figure 1 comprises at least one undulating strand 36 comprising a series of spring elements 34 referred to as hinges or spring hinges that are configured to deform as the heart 30 expands during filling. Each hinge 34 provides substantially unidirectional elasticity, in that it acts in one direction and does not provide much elasticity in the direction perpendicular to that direction. For example, Figure 2A shows one embodiment of a hinge member 34 at rest. The hinge member 34 has a central portion 40 and a pair of arms 42. As the arms are pulled, as shown in Figure 2B, a bending moment 44 is imposed on the central portion 40. The bending moment 44 urges the hinge member 34 back to its relaxed condition. Note that a typical strand comprises a series of such hinges, and that the hinges 34 are adapted to elastically expand and retract in the direction of the strand 36. In the embodiment illustrated in Figure 1, the strands 36 of spring elements 34 are constructed of extruded wire that is deformed to form the spring elements. Although Figure I shows adjacent strands 36 interwoven one with another, it is to be understood that, in additional embodiments, adjacent strands 36 may not overlay or touch one another. Figures 3 and 4 illustrate another preferred embodiment of a cardiac harness 50, shown at two points during manufacture of such a harness. In the illustrated embodiment, the harness 50 is first formed from a relatively thin, flat sheet of material. Any method can be used to force the harness from the flat sheet. For example, in one embodiment, the harness is photochemically etched from the material; in another embodiment, the harness is laser-cut from the thin sheet of material. The embodiment shown in Figures 3 and 4 has been etched from a thin sheet of Nitinol, which is a superelastic material that also exhibits shape memory properties. The flat sheet of material is draped over a form, die or the like, and is formed to generally take on the shape of at least a portion of a heart. With reference to Figures 1 and 4, the illustrated embodiments of the cardiac harnesses 32, 50 comprise a base portion 52, which is sized and configured to generally engage and fit onto a base region of a patient's heart; an apex portion 56, which is sized and shaped so as to generally engage and fit on an apex region of a patient's heart; and a medial portion 58 between the base and apex portions. In the embodiment shown in Figures 3 and 4, the harness 50 comprises strands or rows 36 of undulating wire. As discussed above, the undulations comprise hinges/spring elements 34 which are elastically bendable in a desired direction. Some of the strands 36 are connected to each other by interconnecting elements 60. The interconnecting elements 60 help maintain the position of the strands 36 relative to one another. Preferably the interconnecting elements 60 allow some relative movement between adjacent strands 36. As the~heart expands and contracts during diastole and systole, the contractile cells of the myocardium expand and contract. In a diseased heart, the myocardium may expand such that the cells are distressed and lose at least some contractility. Distressed cells are less able to deal with the stresses of expansion and contraction. As such, the effectiveness of heart pumping decreases. As discussed above, and as discussed in more detail in the applications that are incorporated herein by reference, the undulating spring elements 34 exert a force in resistance to expansion of the heart 30. Collectively, the force exerted by the spring elements tends toward compressing the heart, thus alleviating wall stresses in the heart as the heart expands. Each strand of spring hinges is configured so that as the heart expands during diastole the spring hinges correspondingly expand, storing expansion forces as bending energy in the spring. As such, the stress load on the myocardium is partially relieved by the harness. This reduction in stress helps to decrease the workload of the heart, enabling the heart to ι more effectively pump blood and helping the myocardium cells to remain healthy and/or regain health. It is to be understood that several embodiments of cardiac harnesses can be constructed and that such embodiments may have varying configurations, sizes, flexibilities, etc. yet still create a mildly compressive force on the heart so as to reduce wall stresses. As discussed in the above-referenced applications, such cardiac harnesses can be constructed from many suitable materials including various metals, fabrics, plastics and braided, woven and/or knit filaments. Suitable materials also include superelastic materials and materials that exhibit shape memory. For example, a preferred embodiment of a harness is constructed of Nitinol. Shape memory polymers can also be employed. Such shape memory polymers can include shape memory polyurethanes or other polymers such as those containing oligo(e- caprolactone) dimethacrylate and/or poly(e-caprolactone), which are available from mnemoScience. Further, some cardiac harness embodiments substantially encircle the heart, while others may employ spring members disposed over only a portion of the circumference of the heart or harness. As just discussed, bending stresses are absorbed by the spring members 34 during diastole and are stored in the members as bending energy. During systole, when the heart pumps, the heart muscles contract and the heart becomes smaller. Simultaneously, bending energy stored within the spring members 34 is at least partially released, thereby providing an assist to the heart during systole. In a preferred embodiment, the compressive force exerted on the heart by the spring members of the harness comprises about 10% to 15% of the mechanical work done as the heart contracts during systole. Although the harness is not intended to replace ventricular pumping, the harness substantially assists the heart during systole. With reference next to Figures 5 and 6, another embodiment of a harness 50 comprises strands 36 or strips of undulating wire. As discussed above, the undulations comprise hinges/spring elements 34 which are elastically bendable in a desired direction. The strands of spring elements are oriented in different directions and configured differently in the various portions of the harness. For example, as shown in Figures 5 and 6, in the base portion 52 of the harness, the strands are oriented so that the spring elements 34 will expand and contract in a direction generally transverse to a longitudinal axis of the heart. In the apex region 56, an "archimedes spiral" 62 configuration allows expansion and deformation in more than one direction, but is most compliant in a longitudinal direction. In the medial portion 58, strands 36a are oriented to expand and contract in a generally longitudinal direction. Additionally, some of the strands are connected to each other by interconnecting spring elements 60a, which allow the adjacent strands to move relative to each other in a transverse direction. However, some of the strands 36a in the medial portion 58 are not connected to others of the strands and can move freely relative to one another in a transverse direction. Thus, in the medial portion, the strands are collectively expandable in directions between the longitudinal and transverse directions. In a mammalian heart, the heart muscle cells in the base region tend to expand and contract in a generally transverse direction during pumping of the heart. In the apex region, the heart muscles tend to expand and contract in a longitudinal direction. Between the apex and base regions of the heart, the heart muscles generally expand and contract in directions between the longitudinal and transverse directions. In the embodiment illustrated in Figures 5 and 6, the spring elements 34 are oriented generally in the directions of the cardiac muscle expansion so as to even better resist expansion and alleviate muscle stresses. As such, the arrangement of the base, medial and apex regions 52, 58, 56 of the harness is specially adapted to accommodate the natural expansion and contraction of heart muscle tissue. In this manner, the harness generally mimics the directional contractions typical of heart muscle. With next reference to Figure 7, another embodiment of a cardiac harness 70 is illustrated disposed on a schematically illustrated heart 30. As shown, the cardiac harness 70 is configured to circumferentially surround the heart and extend longitudinally from a base portion 72 to an apex portion 74 of the heart. The harness 70 comprises a plurality of circumferentially extending rings 80 disposed longitudinally adjacent to one another. Each ring 80 comprises a plurality of interconnected spring members 34. The spring members 34 shown in Figure 7 are substantially similar to the spring members 34 discussed above with reference to Figures 2 A and 2B. A plurality of connectors 82 interconnects adjacent rings 80. The connectors 82 have a length oriented longitudinally relative to the rings so as to create space between adjacent rings. Further, the connectors help to maintain proper alignment between adjacent rings, while allowing some relative movement therebetween. The illustrated harness is configured so that no spring members 34 overlap one another. As such, wear of the harness due to repeated flexing and relative movement of the spring members 34 is avoided. Preferably, the connectors 82 are formed of a semi-compliant material, such as silicone or other similar material. It is contemplated that the connectors 82 may comprise any medical grade polymer such as, but not limited to, polyethylene, polypropylene, polyurethane, nylon, PTFE and ePTFE. In the embodiment illustrated in Figure 7, each ring 80 initially comprises an elongate strand comprised of a series of spring members 34. Each strand of spring members 34 preferably is formed of a drawn metallic wire, preferably Nitinol or another metal having a shape memory property. Preferably, the Nitinol wire is shaped into the series of spring members and treated to develop a shape memory of the desired spring member structure. After such treatment, each elongate strand is cut to a length such that when opposite ends of the elongate strand are connected, the elongate strand assumes the ring-shaped configuration shown in Figure 7. It will be appreciated that the lengths of the elongate strands 36 are selected such that the resulting rings 80 are sized in conformity with the general anatomy of the patient's heart 30. More specifically, strands used in the apex portion of the harness are not as long as the strands used to form the base portion. As such, the harness generally tapers from the base 52 toward the apex 54 in order to generally follow the shape of the patient's heart. In another embodiment, the diameter of a ring 80b at the base of the harness is smaller than the diameter of the adjacent ring 80c. In this embodiment, the harness has a greatest diameter at a point between the base and apex ends, and tapers from that point to both the base and apex ends.
Preferably, the point of greatest diameter is closer to the base end 52 than to the apex end 56.
It is contemplated that the lengths of the strands, as well as the sizes of the spring members, may be selected according to the intended size of the cardiac harness 70 and/or the amount of compressive force the harness is intended to impart to the patient's heart. With continued reference to Figure 7, the right side 84 of the base portion 52 of the harness 70 comprises strands 86 of interconnected spring members that are not configured into a ring, but extend only partially about the circumference of the harness 80. Preferably, the partial strands 86 are connected to the adjacent full ring in a manner so that the partial strands are stretched. As such, the partial strands 86 will bend inwardly to "cup" the upper portion of the right atrium, as simulated in Figure 7. In the illustrated embodiment, the rings 80 are coated with dielectric material and the connectors 82 are formed of a nonconductive material. As such, each ring is electrically isolated from the other rings in the harness. Preferably, silicone tubing is advanced over a strand of spring members prior to forming the strand into a ring. In another embodiment,
Nitinol wire is dip coated with an insulating material before or after being formed into rings. Various materials and methods can be used to coat the harness with dielectric material. In the illustrated embodiment, the rings are coated with silicone rubber. Other acceptable materials include urethanes and ceramics, as well as various polymers and the like, including Parylene™, a dielectric polymer available from Union Carbide. The materials can be applied to a harness by various methods, such as dip coating and spraying, or any other suitable method. As discussed above, adjacent rings 80 are joined to one another by connectors 82. In the embodiment illustrated in Figure 7, connectors 82 are generally staggered between adjacent rings 80. It is to be understood that, in other embodiments, different arrangements of connectors 82 can be employed. For example, connectors between adjacent rings can be substantially aligned with one another. In the embodiment illustrated in Figure 7, the connectors 82 comprise silicone rubber.
As such, the connectors are somewhat elastic, and the harness 70 is longitudinally compliant. However, the longitudinal compliance of the harness is limited by the elastic properties of the connectors. Due to both the geometry of the rings and elastic properties of the ring material, the circumferential compliance of the harness 70 is much greater than the longitudinal compliance. In an embodiment wherein connectors between adjacent rings are substantially aligned, the longitudinal compliance of the harness is even more closely limited by the elastic properties of the connectors, and such an embodiment would be less longitudinally compliant than the embodiment of Figure 7. In another embodiment, a harness is constructed of polyester filaments knit in a well known "Atlas knit" arrangement, such as that discussed in international patent Publication Number WO 01/95830 A2, which is incorporated herein by reference in its entirety. As such, the harness is flexible, and the fabric can stretch, even though the polyester filaments do not necessarily elastically deform upon stretching of the fabric. Such fabric stretch is mainly due to linearization of filaments and fiber crimp and geometric distortion of the knit pattern. Once these stretch factors are exhausted, the harness becomes inelastic, and will no longer expand elastically with an increase in size of a patient's heart. When foreign objects or substances, such as a cardiac harness, are introduced onto or adjacent the heart, the body will tend to deposit tissue on or around the foreign object. For example, fibrin and collagen deposits will tend to accumulate on and around the heart after a cardiac harness is placed thereon. This scar tissue tends to be tough, though flexible, and will additionally resist expansion of the patient's heart. In one preferred embodiment, a cardiac wall tension reduction device is constructed of a bioabsorbable material. As such, the device will dissolve after a predetermined period of time. When in place, however, the device will relieve cardiac wall tension. Once the device is installed on the heart, the patient's body will respond by depositing scar tissue on the device and around the heart. Preferably, the tissue at least partially encapsulates the heart. After the device dissolves, the scar tissue remains. Thus, although the implanted device no longer restricts or resists further cardiac expansion, the scar tissue resists such expansion. As such, a long term treatment for resisting further cardiac expansion is established without requiring a permanent implant. A bioabsorbable cardiac wall tension reduction device can be formed of any bioabsorbable material. It is to be understood that many types of materials can be used, including bioabsorbable materials typically used in sutures, stents and the like. For purposes of this disclosure, bioabsorbable materials include materials that degrade or dissolve over time when placed within a human body, and include biodegradable materials. In preferred embodiments, FDA-approved materials such as polylactic acid (PLA) and polyglycolic acid
(PGA) can be used. Other materials, including both synthetic and naturally-derived polymers can suitably be employed. A bioabsorbable cardiac harness can be formed in accordance with any acceptable method and fashion. For example, a sheet of PGA or PLA can be molded to a shape that fits about the heart. Similarly, a sheet can be formed having holes or gaps that lend themselves to increased flexibility. Further, a device can be molded or cut to have a series of undulating spring members, as in the embodiments discussed above. Still further, a lattice structure may be used to provide elasticity and facilitate and/or direct scar growth in a desired manner and direction. Still further, bioabsorbable material can be provided as extruded fibers or filaments that can be woven, braided, knit, or the like so as to fit about the heart and constrain expansion thereof. As discussed in the above-referenced applications, when a force is applied to relieve cardiac wall stresses, the working load on the heart is reduced. Reducing the working load allows the heart to at least partially rest, and appears to provide an opportunity for the heart to at least partially heal itself. For example, it is anticipated that a remodeled diseased heart can reverse-remodel so as to become more healthy if cardiac wall stresses are reduced. The effect of reducing wall stress can indeed lead to valuable and beneficial healing effects. In another preferred embodiment, a cardiac wall tension reduction device is at least partially made of a bioabsorbable material that is combined with medically-beneficial medicaments so that the beneficial medicaments are released as the bioabsorbable material dissolves. For example, bone marrow or stem cells can be provided so as to possibly stimulate myocardial regeneration. This type of treatment may help resolve an infarct, and promote healing of the heart. Of course, it is to be understood that any type of medicament anticipated to aid the heart can be combined with a bioabsorbable apparatus. In another embodiment, a bioabsorbable cardiac harness can be combined with anti- fibrin drugs and/or other medications that resist the deposit or growth of body tissues around the installed harness. As such, the harness reduces heart wall stresses, giving the heart an opportunity to begin healing, but will not form extensive scar tissue. In this embodiment, the harness is adapted so that it will dissolve after a period of time sufficient to rest the heart so that it can continue its work without developing worsening symptoms of disease. Since little or no scar tissue is left behind after the harness dissolves, the rested heart will not be restricted by such tissue. Although, as discussed above, scar tissue can sometimes serve a beneficial purpose, some situations benefit from avoidance of scar tissue. As discussed above, it is anticipated that the heart will reverse remodel when a harness reduces cardiac wall stress. As such, the heart may be smaller when a bioabsorbable harness dissolves than when the harness was installed. In accordance with one embodiment, a new, smaller harness is then to be placed on the heart, thus prompting further reverse remodeling. This process can be repeated as often as desired, until the heart has reached a desired size and health level. When the desired size is achieved, further harnesses may not be needed because the heart is healthy enough to maintain its size. Alternatively, a permanent harness may be installed to maintain the heart at the desired size. In a further embodiment, another bioabsorbable harness is installed, but without anti-tissue-growth drugs. As such, the heart becomes at least partially encapsulated in body tissues that will resist enlargement of the heart beyond the desired size. This helps the heart maintain the desired healthy size. In still another preferred embodiment, foreign bodies are introduced about the heart so as to stimulate tissue growth that will at least partially encapsulate the heart. These foreign bodies need not be in the form of a cardiac harness, and need not impart any compressive force on the heart. However, these foreign bodies will stimulate fibrin/collagen or other tissue growth about the heart so as to at least partially encapsulate the heart in the tissue. The tissue will act as a sock or jacket to resist further expansion of the heart. It is to be understood that such foreign matter can be bioabsorbable, but is not necessarily so. For example, the foreign matter can comprise a liquid or powder irritant specially adapted to stimulate fibrin or collagen growth. Such irritants may include shredded or powderized polyester or other plastics. In another embodiment, foreign matter or a cardiac harness can be arranged around the heart so as to stimulate tissue growth at specified locations and in desired directions. For example, matter can be placed so as to stimulate tissue growth in a configuration that generally follows the directional expansion and contraction of heart muscle. For example, in Figure 8, foreign material is arranged on or around the heart 30 in a series of strips 90 which are arranged to generally correspond to the directional expansion and contraction of heart muscle. This prompts tissue growth in the area and directional configuration of the strips 90. As such, the tissue grows to generally correspond to the directional expansion and contraction of heart muscle. Such tissue will help reduce the muscle load as the heart expands during filling and contracts during pumping. Preferably, the foreign matter that stimulates the tissue growth comprises a bioabsorbable material. In another embodiment, the foreign matter is not bioabsorbable and is maintained permanently in the patient's body. Introduction and placement of foreign material around the patient's heart can be performed via minimally-invasive methods. Minimally invasive methods can also be used to install a Nitinol, woven and/or bioabsorbable harness around the heart. Even less invasive methods can be used to place loose or detached foreign matter about the heart. As a patient's heart enlarges during congestive heart failure, the armulus of certain valves, such as the mural valve, tends to grow with the heart. Eventually, the valve a mulus may increase in size to a point at which the leaflets are not large enough to completely close the valve. Another factor contributing to valve dysfunction is that as the heart enlarges, the geometry of the heart changes somewhat. Portions of the heart, such as the papillary muscles, are moved outwardly from the leaflets to which the papillary, muscles are attached via the chordae tendinaea. These papillary muscles may be stretched so much that they prevent the valve leaflets from adequately engaging each other during valve closure. As such, the leaflets will not be able to fully close, and the valve will leak. Such valve leakage simply makes the patient's heart problems worse. As discussed in the above-referenced application entitled "Heart Failure Treatment
Device and Method", a harness or collar can be configured to exert a compressive force on specific portions of a heart so as to help prevent or diminish valve dysfunction. For example, a collar-type device can be specially configured to fit around the AV groove region 92 of the heart 30. Figure 9 shows an AV groove collar 94 arranged and configured to exert a compressive force that will tend to decrease the size of the valvular annuli and/or prevent enlargement of the valvular annuli beyond desired sizes. With continued reference to Figure 9, a papillary muscle band 96 can be configured to be placed around the outside of the heart 30 in the area of the papillary muscles. As lαiown in the art, the papillary muscles are generally midway between the AV groove and the apex of the heart. Thus, a papillary muscle band 96 can exert a compressive force to reduce the diameter of the heart at the level of the papillary muscles. This will help the papillary muscles become less stretched so that they allow and facilitate closure of the valve leaflets. In the illustrated embodiment, the papillary band 96 is constructed of a woven or knit fabric. It is to be understood that the papillary band 96 can also have an undulating spring hinge construction such as that shown and discussed in connection with the embodiments presented in FIGURES 1-7. Further, the AV groove collar 94 and/or papillary muscle band 96 can be constructed of a substantially elastic material, such as silicone rubber. As discussed above, a cardiac harness applies a mild compressive force on a patient's heart. It is anticipated that embodiments of an AV groove collar 94 and papillary muscle band 96 will exert a more aggressive compressive force than a typical cardiac harness. In another embodiment, a permanent cardiac harness implant is coated with an irritant in the portions configured to engage the AV groove 92 and/or papillary muscle regions of the heart so as to provide a more dramatic stimulus for tissue growth in these portions. Thus, tissue growth in the AV groove and papillary muscle areas of the heart will be increased, providing further resistance to expansion in these areas. In another embodiment, a bioabsorbable woven or knit AV groove collar 94 stimulates tissue growth in and around the AV groove so as to provide similar benefits without a permanent implant. A bioabsorbable papillary muscle band 96 is similarly provided. It is to be understood that the AV groove collar 94 and papillary muscle band 96 can be used independent of one another or in conjunction with one another and either independent of or in conjunction with a permanent or bioabsorbable cardiac harness. For example, a papillary muscle band can be placed on the heart before or after installation of a cardiac harness. In still further embodiments, an AV groove collar 94 and papillary band 96 can be incorporated into a cardiac harness so as to apply specially-directed forces to the specific portions of the heart and to create specific regions of increased tissue growth. In still another embodiment, an AV groove collar and/or papillary band is constructed of a bioabsorbable material and is configured to exert a force on a patient's heart within a first force range. A cardiac harness is provided and is configured to exert a force on the patient's heart within a second force range. The first range of force, which is to be exerted by the papillary band or AV groove collar, induces generally greater levels of force than the second range. As such, when the combination is installed on the patient's heart, a greater force is exerted at the AV groove or papillary band region of the heart than elsewhere. As time passes and the collar or band is absorbed, the applied force on the heart becomes more equalized. This arrangement enables treatment of acute valvular dysfunction by applying a greater degree of force in one area of the heart than is needed for the rest of the heart. Over time, as the rest of the heart remodels, no extra force is needed to treat valvular dysfunction and, in this embodiment, is no longer exerted. In a variation of the above embodiment, the AV groove collar and/or papillary muscle band is formed from a bioabsorbable material and is configured to have a maximum dimension beyond which the collar/band will not deform. As such, a selected portion of the heart can be constrained to a specific size while the rest of the heart is not so constrained. This enables passive treatment of the heart as a whole while also addressing an acute issue. It is to be understood that, in other embodiments, a bioabsorbable member can temporarily apply a targeted, increased force in a desired portion of the patient's heart while an accompanying cardiac harness provides a more even, mild and permanent compressive force over a larger portion of the heart. In the embodiments described above, the cardiac harness preferably applies a mild compressive force on the heart in order to achieve therapeutic benefits. An applied force or pressure within a therapeutic range is defined herein as a pressure of sufficient magnitude that, when applied to an organ such as the heart, results in a benefit to the organ. In one embodiment, the therapeutic range for a cardiac harness is between about 2-20 mmHg. More preferably, the therapeutic pressure is about 2-10 mmHg, and most preferably is between about 2-5 mmHg. With reference next to Figure 10, a pressure versus percentage tensile strain curve 100 is presented reflecting actual test data for one embodiment of a cardiac harness constructed of drawn Nitinol wire formed into undulating spring hinges. As shown, this harness embodiment is capable of extensive deformation. In this embodiment, the harness is stretched from its original, at-rest position in order to be fit over the patient's heart. When on the heart, it applies a mild, compressive force, which will tend to help the heart reverse-remodel. As the heart reverse-remodels and becomes smaller, the harness correspondingly becomes smaller. Of course, the size of the heart varies between the beginning of diastole and the end of diastole. In the illustrated embodiment, the labels Ds and DF have been applied to the curve to identify the pressure applied by the harness at a particular level of tensile strain ε corresponding to the beginning Ds and end Dp of diastole. In a similar manner the labels D's, and D illustrate the relative pressures applied by the harness at the beginning and end of diastole as the heart reverse remodels and becomes smaller. In the illustrated embodiment, the cardiac harness adjusts continuously with the heart as the heart changes in size, and also applies a therapeutic pressure to the heart even when the heart reverse remodels extensively. In the illustrated embodiment, the cardiac harness exerts a pressure in response to strain of the harness. For example, if the harness is strained about 100%, it will exert about lOmmHg on the heart. As the heart becomes smaller as a result of reverse remodeling, the percent strain of the harness will decrease, and the corresponding pressure exerted by the harness also will decrease. In the preferred embodiment, the harness is configured so that the applied pressure varies relatively little over a broad range of deformation. As such, the harness provides a therapeutic pressure even after the heart has reverse remodeled extensively. For example, with continued reference to Figure 10, a reduction in size corresponding to a 40%) change in strain as the harness reduces from 100% to 60% strain is accompanied by a decrease in applied pressure of less than about 3mmHg. A 40% change from 80% to 40% strain is accompanied by a decrease in applied pressure of less than about 4mmHg. Still further, a 20% reduction in size can be accompanied by a decrease in applied pressure of less than about 3mmHg or, depending on the degree of strain of the harness, less than about 2mmHg. Additional relationships indicating changes in applied pressure corresponding to changes in the size/strain of the harness can be derived from the illustrated pressure/strain curve of Figure 10. In accordance with another embodiment, the harness represented by the test data of
Figure 10 is coated with a bioabsorbable coating including a medicament that inhibits growth of tissue in response to introduction of a foreign body. As such, scar tissue growth around the heart and harness will be minimized, and the harness can dramatically decrease in size as the heart reverse remodels without scar tissue preventing the harness from adjusting and changing shape with the patient's heart. With reference next to Figures 11 and 12, applicants have developed a method and apparatus for testing the elastic behavior of a cardiac harness. Figure 11 shows an elongate test portion 110 that is taken from a cardiac harness. In the illustrated embodiment, the test portion 110 has been taken from the harness 70 of Figure 7 generally along the lines 11-11. However, it is to be understood that a test portion can be taken from nearly any portion of a harness so long as the test portion comprises a substantial enough portion of the harness so as to properly represent the harness during materials testing. With continued reference to Figure 11, the test portion 110 preferably has a length L and a width W. The length L is defined in a direction generally along the circumference of the harness. In other words, the length L is taken in a direction generally transverse to a longitudinal axis of the heart and harness. Most preferably, the length L is taken in the direction generally perpendicular to the longitudinal axis. The width W extends in a direction generally along the longitudinal axis. With reference next to Figure 12, the test portion 110 preferably is placed in a material property testing machine 112 such as is available from Instron™. The test portion 110 of the harness preferably is disposed in mounts 114 of the materials testing machine 112, and the machine pulls the test portion 110 along its length L. The materials testing machine 112 collects data detailing the load, in pounds force (lbF), and the corresponding percent tensile strain of the test portion 110 along the length L. The load is then normalized with reference to the width W of the test portion which, in the illustrated embodiment, is in a longitudinal direction. Thus, in the illustrated embodiment, load data is taken in the units of
IbF/in. The above-described test procedure allows measurement of the elasticity/deformation behavior of various embodiments of cardiac harnesses so that such embodiments can be compared. For consistency, testing preferably is performed at room temperature, preferably about 37° C. As discussed above, the load is applied along the length L of the test portion
110, which length L is taken in a direction along the circumference of the corresponding harness. Thus, the applied load represents and corresponds to a circumferential load of the harness. The percent tensile strain is also taken along the length L. As such, the percent tensile strain represents and corresponds to a percent of circumferential expansion of the harness above a zero load condition. With reference next to Figure 13, an anticipated compliance curve charting the compliance of one embodiment of a cardiac harness is presented. The illustrated graph represents behavior of a cardiac harness constructed of a knit material such as a harness constructed employing an "atlas knit" as discussed above. As shown in the drawing, the tested embodiment appears generally parabolic in shape. That is, as the percent tensile strain increases the corresponding load increases exponentially. In the illustrated embodiment, it is anticipated that an asymptote will be defined at a percent strain between about 40%-50%. At that point the test portion will have reached its limit of expansion. With reference next to Figure 14, an exemplary spring element 34 of a harness such as the harness 70 of Figure 7 is illustrated. The spring element 34 of Figure 14 represents one element from a strand of such spring elements. This figure will be used to define the dimensions of some specific embodiments for which test data has been obtained. With reference also to Figure 15, plotted test data is presented for a test portion of a cardiac harness. The cardiac harness exemplified by the test data of Figure 15 comprises strands of spring elements preferably formed of drawn Nitinol wire having a diameter of about 0.008 in.The spring elements resemble the spring element 34 shown in Figure 14, and have a width w of about 0.165 in., a height h of about 0.163 in., and a diameter Φ of about 0.126 in. After the wire is formed into strands of spring elements, it is heat treated at about 485° C for about 30 minutes. Silicone tubing having an inner diameter of about 0.010 in. and an outer diameter of about 0.025 in. is disposed over the strand. A test portion of the just-described cardiac harness was tested in a materials testing machine in accordance with the procedure discussed above. Test data, including load and percent tensile strain, was collected between a zero load, zero percent strain condition and about a 100% strain condition. Representative test data points are set out in the plot of Figure
15, in which percent tensile strain is plotted along the x axis, and load, normalized with respect to the width W of the test portion, is plotted along the y axis. With continued reference to Figure 15, a linear regression of the test data was performed in order to derive a function describing the behavior of the cardiac harness in the form y = ax + b. The linear regression was performed using Microsoft™ Excel™ software, and yielded the function y = O.OOlx + 0.005. The linear regression function has a coefficient of determination R2 of about 0.9969. It is understood that, in linear regression, the coefficient of determination R2 represents how well the linear regression function represents the collection of data. In the illustrated embodiment the R2 value is very close to 1, and thus indicates that the linear regression line closely represents the data. With reference next to Figure 16, plotted test data is presented for a test portion of another embodiment of a cardiac harness. The cardiac harness exemplified by the test data of Figure 16 comprises strands of spring elements preferably formed of drawn Nitinol wire having a diameter of about 0.012 in. The spring elements resemble the spring element 34 shown in Figure 14, and have a width w of about 0.300 in., a height h of about 0.275 in., and a diameter φ of about 0.250 in. After the wire is formed into strands of spring elements, it is heat treated at about 485° C for about 30 minutes. Silicone tubing having an inner diameter of about 0.014 in. and an outer diameter of about 0.029 in. is disposed over the strand. A test portion of the just-described cardiac harness was tested in a materials testing machine in accordance with the procedure discussed above. Test data, including load and percent tensile strain, was collected between a zero load, zero percent strain condition and about a 100% strain condition. Representative test data points are set out in the plot of Figure
16, in which percent strain is plotted along the x axis, and load, normalized with respect to the width W of the test portion, is plotted along the y axis. With continued reference to Figure 16, a linear regression of the test data was performed in order to derive a function describing the behavior of the cardiac harness in the form y = ax + b. The linear regression was performed using Microsoft™ Excel™ software, and yielded the function y = 0.0009x + 0.0083. The linear regression function has a coefficient of determination R2 of about 0.9864. With reference next to Figure 17, plotted test data is presented for a test portion of yet another embodiment of a cardiac harness. The cardiac harness exemplified by the test data of Figure 17 comprises strands of spring elements preferably formed of drawn Nitinol wire having a diameter of about 0.012 in. The spring elements resemble the spring element 34 shown in Figure 14, and have a width w of about 0.300 in., a height h of about 0.275 in., and a diameter φ of about 0.250 in. After the wire is formed into strands of spring elements, it is heat treated at about 485° C for about 30 minutes. Silicone tubing having an inner diameter of about 0.014 in. and an outer diameter of about 0.029 in. is disposed over the strand. As can be seen, the cardiac harness represented in Figure 17 is structurally very similar to the cardiac harness represented in Figure 16. In fact, the most significant difference between the harnesses is found in the arrangement of connectors between adjacent strands. As discussed above, due to the differences in connector placement, the longitudinal compliances of these embodiments are somewhat different. However, as set out below, the circumferential compliance of these embodiments is quite similar. A test portion of the just-described cardiac harness was tested in a materials testing machine in accordance with the procedure discussed above. Test data, including load and percent tensile strain, was collected between a zero load, zero percent strain condition and about a 100% strain condition. Representative test data points are set out in the plot of Figure 17, in which percent strain is plotted along the x axis, and load, normalized with respect to the width W of the test portion, is plotted along the y axis. With continued reference to Figure 17, a linear regression of the test data was performed in order to derive a function describing the behavior of the cardiac harness in the form y = ax + b. The linear regression was perfoπned using Microsoft™ Excel™ software, and yielded the function y = 0.0009x + 0.0073. The linear regression function has a coefficient of determination R2 of about 0.9933. With reference next to Figure 18, plotted test data is presented for a test portion of another embodiment of a cardiac harness. The cardiac harness exemplified by the test data of Figure 18 comprises strands of spring elements preferably formed of drawn Nitinol wire having a diameter of about 0.011 in. The spring elements resemble the spring element 34 shown in Figure 14, and have a width w of about 0.165 in., a height h of about 0.163 in., and a diameter φ of about 0.126 in. After the wire is formed into strands of spring elements, it is heat treated at about 485° C for about 30 minutes. Silicone tubing is disposed over the strand. A test portion of the just-described cardiac harness was tested in a materials testing machine in accordance with the procedure discussed above. Test data, including load and percent tensile strain, was collected between a zero load, zero percent strain condition and about a 100% strain condition. Representative test data points are set out in the plot of Figure 18, in which percent strain is plotted along the x axis, and load, normalized with respect to the width W of the test portion, is plotted along the y axis. With continued reference to Figure 18, a linear regression of the test data was performed in order to derive a function describing the behavior of the cardiac harness in the form y = ax + b. The linear regression was performed using Microsoft™ Excel™ software, and yielded the function y = 0.0033x + 0.0238. The linear regression function has a coefficient of determination R2 of about 0.9749. With continued reference to Figure 18, it is observed that the slope of the curve represented by the data points becomes lesser as the percent strain increases. A linear regression of the test data was performed in order to derive a function describing the behavior of the cardiac harness in the form y = ex2 + ax + b. The linear regression was performed using Microsoft™ Excel™ software, and yielded the function y = -0.00005x2 + 0.0054x -
0.0129. This linear regression function has a coefficient of determination R2 of about 0.9989. Yet another embodiment of a cardiac harness comprises strands of spring elements formed of drawn Nitinol wire having a diameter of about 0.016 in. The spring elements resemble the spring element shown in Figure 14, and have a width w of about 0.289 in., a height h of about 0.275 in., and a diameter Φ of about 0.250 in. After the wire is formed into strands of spring elements, it is heat treated at about 515° C for about 25 minutes. Silicone tubing is disposed over the strand. A test portion of the just-described cardiac harness was tested in a materials testing machine in accordance with the procedure discussed above. Test data, including load and percent tensile strain, was collected between a zero load, zero percent strain condition and about a 100% strain condition. A linear regression of the test data was performed in order to derive a function describing the behavior of the cardiac harness in the form y = ax + b. The linear regression was performed using Microsoft™ Excel™ software, and yielded the function y = 0.003x + 0.0073. The linear regression function has a coefficient of determination R2 of about 0.9945. In each of the embodiments discussed above, the compliance functions y=ax+b are determined based on test data between about zero percent strain and 100% strain. It is anticipated that behavior of the harness test portions may change considerably if tested far beyond 100% strain. However, it is to be understood that the tested range of expansion of about 0-100%) represents a proposed operating range of expansion for each harness. In this operating range, the compliance behavior of the harness embodiments is known and predictable. In accordance with one embodiment, the cardiac harness is sized and configured relative to a patient's heart so that the operating range of the harness is up to about 75% expansion. In another embodiment, the operating range of the harness is up to about 50% expansion. Although the tested embodiments have been tested only up to about 100% expansion, it is to be understood that further testing may reveal acceptable behavior in ranges well above 100% expansion. As such, an operating range of the harness should be taken to mean a range over which the compliance behavior of the harness is acceptable for its intended purpose of providing a mild compressive force to the patient's heart without defining a limit beyond which the heart cannot expand. Further, it is to be understood that, by employing the compliance functions that are derived from the test data by linear regression, the compliance behavior of the associated harnesses can be predicted over any range of expansion or load. For example, with reference to the embodiment of Figure 18, it can be determined that a change of about 20 percent in circumferential expansion within an operating range of expansion having a minimum value of at least 20 percent yields a change in circumferential load of about 0.066 lb/in. With reference to the embodiment of Figure 15, it can be determined that a change of about 20 percent in circumferential expansion within an operating range of expansion between about 0 and 100 percent yields a change in circumferential load of about 0.02 lb/in. Experimental studies indicate that a cardiac harness having compliance properties as in the embodiment of Figure 15 provide a beneficial therapeutic effect to a diseased heart. Studies also indicate that a cardiac harness having compliance properties as in the embodiment of Figure 18 also provides a beneficial therapeutic effect. Preferably, however, a cardiac harness has compliance properties at or more compliant than the embodiment of Figure 18. Thus, preferably a change of about 20 percent in circumferential expansion yields a change in circumferential load no greater than about 0.066 lb/in. As demonstrated by the several embodiments tested and discussed above, significant changes to the calculated compliance functions can be achieved by varying structural properties such as wire diameter, heat treatment, and dimensions of spring elements. It is anticipated that other cardiac harness embodiments can be constructed wherein a change of about 20 percent in circumferential expansion yields a change in circumferential load of about 0.066 lb/in., 0.02 lb/in., 0.018 lb/in., or any range between or below these values. Testing harness embodiments as discussed above enables analysis of the behavior of the harness over its operating range. For example, the compliance function y=ax+b can be computed over the entire range of test data, as with the embodiments discussed above, or can be computed over only a selected range of test data. Pursuant to standard mathematical properties, the constant "a" represents the slope of the function. With reference to the embodiment of Figure 18, the slope of the test data declines as the percent expansion increases. As such, if a first slope "a" is calculated by linear regression over a first selected range of expansion, and a second slope "a" is calculated over a second selected range of expansion, which second range consists of expansion values greater than the first range, the second slope "a" will be less than the first slope "a". In other embodiments, such as that of Figure 16, the second slope "a" will be nearly the same as, but no greater than the first slope "a" for at least portions of the test data. Preferably, each of the first and second ranges of data comprise a significant range of data, such as over at least five percent of expansion. The analysis just discussed is helpful in analyzing cardiac harness compliance behavior to determine whether a cardiac harness exhibits desired behavior. For example, in a preferred embodiment, the second slope "a" is no greater than the first slope "a". It is further helpful to analyze such behavior over only portions of the range of expansion that are expected to be used during operation of the harness. For example, in another prefeπed embodiment, the second slope "a" is no greater than the first slope "a" within an operational range of expansion of the harness of about 0-100 percent expansion. In further preferred embodiments, the first selected range of expansion is within a range between about 20 and 30 percent expansion, and the second selected range of expansion is within a range between about 25 and 100 percent expansion. In yet another embodiment, the second selected range of expansion is within a range between about 25 and 50 percent expansion. In the embodiments discussed above, the compliance function has been defined by linear regression of test data taken over a percent expansion between about 0-100%>. It is to be understood that such an analysis may also be helpful if taken over a more limited range of percent expansion. For example, the operating range of the harness may, in some embodiments, be limited to such a range of expansion. In accordance with one embodiment, the variation of load as a function of expansion between about 20 - 30 percent expansion is represented by the compliance function y=ax+b in which "a" and "b" are determined by linear regression, and wherein the value of "a" is no greater than about 0.0033. In the illustrated embodiments, the coefficients of determination have been very close to 1. More particularly, the coefficients of determination are greater than about 0.9 band, in some embodiments, greater than about 0.98. Preferably, a compliance function determined by linear regression has a coefficient of determination of at least about 0.8 in order to be helpful for analysis as discussed herein. For each of the analyses discussed above, characteristics over certain exemplary ranges of expansion have been specifically discussed. It is to be understood that, at least for the test data and corresponding compliance functions disclosed herein, the properties of the corresponding harnesses can be analyzed over any range of circumferential expansion or load. Such varying ranges of analysis are contemplated by the test data and the compliance functions. Such analyses are advantageous for defining the behavior of the conesponding harness embodiment. Although this invention has been disclosed in the context of several preferred embodiments and examples, it will be understood by those skilled in the art that the present invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the invention and obvious modifications and equivalents thereof. In addition, while a number of variations of the invention have been shown and described in detail, other modifications, which are within the scope of this invention, will be readily apparent to those of skill in the art based upon this disclosure. It is also contemplated that various combinations or subcombinations of the specific features and aspects of the embodiments may be made and still fall within the scope of the invention. Accordingly, it should be understood that various features and aspects of the disclosed embodiments can be combined with or substituted for one another in order to form varying modes of the disclosed invention. Thus, it is intended that the scope of the present invention herein disclosed should not be limited by the particular disclosed embodiments described above, but should be determined only by a fair reading of the claims that follow.

Claims

WHAT IS CLAIMED: 1. A cardiac harness configured to fit generally around a patient's heart and to resist expansion of the heart by applying a compressive force thereto, at least a section of said harness exerting a circumferential load, normalized with respect to a longitudinal direction and expressed in pounds per inch, as a function of circumferential expansion of said section of harness, expressed as a percent of expansion above a zero load condition, said harness having an operating range of expansion having a minimum value of at least 20 percent, wherein a change of 20 percent in said circumferential expansion within said operating range yields a change in circumferential load of no more than about 0.066 lb/in. 2. The cardiac harness of Claim 1, wherein the section encompasses at least a substantial portion of the harness. 3. The cardiac harness of Claim 1, wherein a change of 20 percent in said circumferential expansion within said operating range yields a change in circumferential load of no more than about 0.064 lb/in. 4. The cardiac harness of Claim 1, wherein a change of 20 percent in said circumferential expansion within said operating range yields a change in circumferential load of no more than about 0.05 lb/in. 5. The cardiac harness of Claim 1, wherein a change of 20 percent in said circumferential expansion within said operating range yields a change in circumferential load of no more than about 0.02 lb/in. 6. The cardiac harness of Claim 1, wherein a change of 20 percent in said circumferential expansion within said operating range yields a change in circumferential load of no more than about 0.018 lb/in. 7. The cardiac harness of Claim 1, wherein the operating range of expansion has a minimum value of at least about 25 percent. 8. The cardiac harness of Claim 1, wherein the circumferential compliance of the harness over the operating range of expansion is greater than a longitudinal compliance of the harness. 9. A cardiac harness configured to fit generally around a patient's heart and to resist expansion of the heart by applying a compressive force thereto, at least a section of said harness exerting a circumferential load, normalized with respect to a longitudinal direction and expressed in pounds per inch, as a function of circumferential expansion of said section of harness, expressed as a percent of expansion above a zero load condition, the variation of load as a function of expansion through a selected range of expansion being generally in the form of y=ax+b where a and b are determined by linear regression, a first value of "a" corresponding to a first selected range of expansion of at least 5 percent, and a second value of "a" corresponding to a second selected range of expansion of at least 5 percent, the second range of expansion consisting of values greater than the first range of expansion so as to be non-overlapping with the first range, said second value of "a" being no greater than said first value of "a". 10. The cardiac harness of Claim 9, wherein the first and second ranges are substantially contiguous with one another. 11. The cardiac harness of Claim 9, wherein the first and second selected ranges of expansion are within an operational range of expansion of the harness of about 0-100 percent expansion. 12. The cardiac harness of Claim 11, wherein the first selected range of expansion is within a range between about 20 and 30 percent expansion. 13. The cardiac harness of Claim 12, wherein the second selected range of expansion is within a range between about 25 and 100 percent expansion. 14. The cardiac harness of Claim 12, wherein the second selected range of expansion is within a range between about 25 and 70 percent expansion. 15. The cardiac harness of Claim 12, wherein the second selected range of expansion is within a range between about 25 and 50 percent expansion. 16. The cardiac harness of Claim 15, wherein the second selected range of expansion is within a range between about 25 and 35 percent expansion. 17. The cardiac harness of Claim 15, wherein the second selected range of expansion is within a range between about 30 and 40 percent expansion. 18. The cardiac harness of Claim 15, wherein the second selected range of expansion is within a range between about 35 and 45 percent expansion. 19. The cardiac harness of Claim 15, wherein the second selected range of expansion is within a range between about 40 and 50 percent expansion. 20. The cardiac harness of Claim 9, wherein the first value of "a" is greater than the second value of "a". 21. A cardiac harness configured to fit generally around a patient's heart and to resist expansion of the heart by applying a compressive force thereto, at least a section of said harness exerting a circumferential load, normalized with respect to a longitudinal direction and expressed in pounds per inch, as a function of circumferential expansion of said section of harness, expressed as a percent of expansion above a zero load condition, the variation of load as a function of expansion between 20 percent expansion and 30 percent expansion being generally in the fonn of y=ax+b where "a" and "b" are determined by linear regression, said linear regression of said variation of load as a function of expansion yielding a coefficient of determination of at least about 0.8, the value of "a" being no greater than about 0.0033. 22. The cardiac harness of Claim 21, wherein the value of "a" is no greater than about 0.0032. 23. The cardiac harness of Claim 21, wherein the value of "a" is no greater than about 0.0025. 24. The cardiac harness of Claim 21, wherein the value of "a" is no greater than about 0.002. 25. The cardiac harness of Claim 21, wherein the value of "a" is no greater than about 0.001. 26. The cardiac harness of Claim 21, wherein the value of "a" is no greater than about 0.0009. 27. The cardiac harness of Claim 21, wherein the coefficient of determination is at least about 0.9. 28. The cardiac harness of Claim 21, wherein the coefficient of determination is at least about 0.95. 29. A cardiac harness configured to fit generally around a patient's heart and to resist expansion of the heart by applying a compressive force thereto, at least a section of said harness exerting a circumferential load, normalized with respect to a longitudinal direction and expressed in pounds per inch, as a function of circumferential expansion of said section of harness, expressed as a percent of expansion above a zero load condition, the variation of load as a function of expansion through a selected range of expansion being generally in the form of y=cx2+ax+b where c, a and b are determined by linear regression, and c is negative. 30. The cardiac harness of Claim 29, wherein the linear regression function has a coefficient of determination of at least about 0.9. 31. The cardiac harness of Claim 29, wherein the linear regression function has a coefficient of determination of at least about 0.99. 32. The cardiac harness of Claim 29, wherein the selected range of circumferential expansion is between about 0 and 100 percent. 33. The cardiac harness of Claim 32, wherein the selected range of circumferential expansion is between about 20-50 percent.
PCT/US2004/035256 2003-10-31 2004-10-22 Cardiac harness WO2005046517A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002541890A CA2541890A1 (en) 2003-10-31 2004-10-22 Cardiac harness
EP04818599A EP1677702A1 (en) 2003-10-31 2004-10-22 Cardiac harness
JP2006538143A JP2007512040A (en) 2003-10-31 2004-10-22 Heart harness

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/698,237 2003-10-31
US10/698,237 US7022063B2 (en) 2002-01-07 2003-10-31 Cardiac harness

Publications (1)

Publication Number Publication Date
WO2005046517A1 true WO2005046517A1 (en) 2005-05-26

Family

ID=34590674

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/035256 WO2005046517A1 (en) 2003-10-31 2004-10-22 Cardiac harness

Country Status (5)

Country Link
US (3) US7022063B2 (en)
EP (1) EP1677702A1 (en)
JP (1) JP2007512040A (en)
CA (1) CA2541890A1 (en)
WO (1) WO2005046517A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951534B2 (en) * 2000-06-13 2005-10-04 Acorn Cardiovascular, Inc. Cardiac support device
US6482146B1 (en) * 2000-06-13 2002-11-19 Acorn Cardiovascular, Inc. Cardiac disease treatment and device
DK1423066T3 (en) 2001-09-07 2008-11-17 Mardil Inc Method and apparatus for external cardiac stabilization
US7022063B2 (en) * 2002-01-07 2006-04-04 Paracor Medical, Inc. Cardiac harness
US7229405B2 (en) * 2002-11-15 2007-06-12 Paracor Medical, Inc. Cardiac harness delivery device and method of use
US7189203B2 (en) * 2002-11-15 2007-03-13 Paracor Medical, Inc. Cardiac harness delivery device and method
US7789979B2 (en) * 2003-05-02 2010-09-07 Gore Enterprise Holdings, Inc. Shape memory alloy articles with improved fatigue performance and methods therefor
CA2530429A1 (en) * 2003-07-10 2005-01-27 Paracor Medical, Inc. Self-anchoring cardiac harness
US20070106336A1 (en) * 2003-11-07 2007-05-10 Alan Schaer Cardiac harness assembly for treating congestive heart failure and for pacing/sensing
US7158839B2 (en) * 2003-11-07 2007-01-02 Paracor Medical, Inc. Cardiac harness for treating heart disease
US20070055091A1 (en) * 2004-12-02 2007-03-08 Lilip Lau Cardiac harness for treating congestive heart failure and for defibrillating and/or pacing/sensing
US7155295B2 (en) * 2003-11-07 2006-12-26 Paracor Medical, Inc. Cardiac harness for treating congestive heart failure and for defibrillating and/or pacing/sensing
US20070106359A1 (en) * 2003-11-07 2007-05-10 Alan Schaer Cardiac harness assembly for treating congestive heart failure and for pacing/sensing
US20050187620A1 (en) * 2003-11-14 2005-08-25 Suresh Pai Systems for heart treatment
US20070100199A1 (en) * 2005-11-03 2007-05-03 Lilip Lau Apparatus and method of delivering biomaterial to the heart
US20070208217A1 (en) 2006-03-03 2007-09-06 Acorn Cardiovascular, Inc. Self-adjusting attachment structure for a cardiac support device
US20070287883A1 (en) * 2006-06-07 2007-12-13 Lilip Lau Apparatus and method for pulling a cardiac harness onto a heart
US8192351B2 (en) 2007-08-13 2012-06-05 Paracor Medical, Inc. Medical device delivery system having integrated introducer
US8092363B2 (en) 2007-09-05 2012-01-10 Mardil, Inc. Heart band with fillable chambers to modify heart valve function
US20110237872A1 (en) * 2008-09-24 2011-09-29 Micardia Corporation Dynamic heart harness
US10220128B1 (en) * 2008-11-06 2019-03-05 Allan R. Robinson Implanted cardiac device to treat heart failure
WO2012071567A2 (en) 2010-11-23 2012-05-31 Lillehei Theodore J Pneumatic or hydraulic cardiac assist devices
WO2013177460A1 (en) 2012-05-23 2013-11-28 Lillehei Theodore J Pneumatic or hydraulic cardiac assist devices
WO2014059433A2 (en) 2012-10-12 2014-04-17 Mardil, Inc. Cardiac treatment system and method
USD717954S1 (en) 2013-10-14 2014-11-18 Mardil, Inc. Heart treatment device

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE29517393U1 (en) * 1995-11-03 1996-02-01 Hohmann Claas Dr Med Pericardial prosthesis
US6416459B1 (en) * 1997-06-21 2002-07-09 Acorn Cardiovascular Inc. Bag for at least partially enveloping a heart
US6482146B1 (en) * 2000-06-13 2002-11-19 Acorn Cardiovascular, Inc. Cardiac disease treatment and device

Family Cites Families (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1682119A (en) 1928-08-28 Cleaning device
US2278926A (en) 1941-02-15 1942-04-07 Metal Textile Corp Knitted metallic fabric for belting and other uses
US2826193A (en) 1956-08-01 1958-03-11 Vineberg Heart Foundation Cardiac resuscitation device
FR92798E (en) 1966-09-05 1968-12-27 Rhone Poulenc Sa New cardiac assistance prosthesis and its manufacture.
FR1512372A (en) 1966-12-19 1968-02-09 Deformable membrane by internal action
US3587567A (en) 1968-12-20 1971-06-28 Peter Paul Schiff Mechanical ventricular assistance assembly
US3613672A (en) 1969-07-09 1971-10-19 Peter Schiff Mechanical ventricular assistance cup
US3988782A (en) 1973-07-06 1976-11-02 Dardik Irving I Non-antigenic, non-thrombogenic infection-resistant grafts from umbilical cord vessels and process for preparing and using same
US3966401A (en) 1974-07-01 1976-06-29 Hancock Laboratories Incorporated Preparing natural tissue for implantation so as to provide improved flexibility
US4065816A (en) 1975-05-22 1978-01-03 Philip Nicholas Sawyer Surgical method of using a sterile packaged prosthesis
US4011947A (en) 1975-05-22 1977-03-15 Philip Nicholas Sawyer Packaged prosthetic device
US3983863A (en) 1975-06-02 1976-10-05 American Hospital Supply Corporation Heart support for coronary artery surgery
US4061134A (en) 1975-10-28 1977-12-06 Samuels Peter B Arterial graft device
US4048990A (en) 1976-09-17 1977-09-20 Goetz Robert H Heart massage apparatus
US4192293A (en) 1978-09-05 1980-03-11 Manfred Asrican Cardiac assist device
JPS6037734B2 (en) 1978-10-12 1985-08-28 住友電気工業株式会社 Tubular organ prosthesis material and its manufacturing method
ES474582A1 (en) 1978-10-26 1979-11-01 Aranguren Duo Iker Process for installing mitral valves in their anatomical space by attaching cords to an artificial stent
US4211325A (en) 1979-06-07 1980-07-08 Hancock Laboratories, Inc. Heart valve holder
US4372293A (en) 1980-12-24 1983-02-08 Vijil Rosales Cesar A Apparatus and method for surgical correction of ptotic breasts
GB2115287B (en) 1981-06-29 1985-10-30 Devendra Nath Sharma Devices for replacing or assisting the heart
US4428375A (en) 1982-02-16 1984-01-31 Ellman Barry R Surgical bag for splenorrhaphy
IT1155105B (en) 1982-03-03 1987-01-21 Roberto Parravicini PLANT DEVICE TO SUPPORT THE MYOCARDIUM ACTIVITY
US4403604A (en) 1982-05-13 1983-09-13 Wilkinson Lawrence H Gastric pouch
FR2527435B1 (en) 1982-05-28 1988-09-16 Serreau Serge CONSTRUCTION SLEEVE FOR STIMULATION OF BLOOD CIRCULATION
US4545783A (en) 1983-07-11 1985-10-08 Warner-Lambert Company Rigid medical solution container
US5067957A (en) 1983-10-14 1991-11-26 Raychem Corporation Method of inserting medical devices incorporating SIM alloy elements
US4665906A (en) 1983-10-14 1987-05-19 Raychem Corporation Medical devices incorporating sim alloy elements
US5190546A (en) 1983-10-14 1993-03-02 Raychem Corporation Medical devices incorporating SIM alloy elements
US4512471A (en) 1984-04-06 1985-04-23 Angicor Limited Storage unit
US4630597A (en) 1984-04-30 1986-12-23 Adrian Kantrowitz Dynamic aortic patch for thoracic or abdominal implantation
US4628937A (en) 1984-08-02 1986-12-16 Cordis Corporation Mapping electrode assembly
US4690134A (en) 1985-07-01 1987-09-01 Snyders Robert V Ventricular assist device
SE454942B (en) 1986-05-22 1988-06-13 Astra Tech Ab HEART HELP DEVICE FOR INOPERATION IN BROSTHALAN
US4697703A (en) 1986-07-02 1987-10-06 Malcolm Will Joint prosthesis package
US4840626A (en) 1986-09-29 1989-06-20 Johnson & Johnson Patient Care, Inc. Heparin-containing adhesion prevention barrier and process
FR2605214B1 (en) 1986-10-15 1992-01-10 Ethnor PERIHEPATIC PROSTHESIS
SU1604377A1 (en) 1987-02-23 1990-11-07 Благовещенский государственный медицинский институт Artificial pericardium
US4821723A (en) 1987-02-27 1989-04-18 Intermedics Inc. Biphasic waveforms for defibrillation
US4827932A (en) 1987-02-27 1989-05-09 Intermedics Inc. Implantable defibrillation electrodes
US5098369A (en) 1987-02-27 1992-03-24 Vascor, Inc. Biocompatible ventricular assist and arrhythmia control device including cardiac compression pad and compression assembly
US4925443A (en) 1987-02-27 1990-05-15 Heilman Marlin S Biocompatible ventricular assist and arrhythmia control device
US4750619A (en) 1987-08-10 1988-06-14 Osteonics Corp. Package with tray for securing and presenting a sterile prosthetic implant element
US4834707A (en) 1987-09-16 1989-05-30 Evans Phillip H Venting apparatus and method for cardiovascular pumping application
US5031762A (en) 1987-10-07 1991-07-16 Heacox Albert E Three envelope package for sterile specimens
US4838288A (en) 1988-03-14 1989-06-13 Pioneering Technologies, Inc. Heart valve and xenograft washing system
US4960424A (en) 1988-06-30 1990-10-02 Grooters Ronald K Method of replacing a defective atrio-ventricular valve with a total atrio-ventricular valve bioprosthesis
US4863016A (en) 1988-07-25 1989-09-05 Abbott Laboratories Packaging for a sterilizable calibratable medical device
US4976730A (en) 1988-10-11 1990-12-11 Kwan Gett Clifford S Artificial pericardium
FR2639221A1 (en) 1988-11-21 1990-05-25 Perrotin Daniel APPARATUS FOR DIRECTIONAL AND PERIODIC MASSAGE OF A PART OF THE HUMAN BODY
US5186711A (en) 1989-03-07 1993-02-16 Albert Einstein College Of Medicine Of Yeshiva University Hemostasis apparatus and method
FR2645739A1 (en) 1989-04-14 1990-10-19 Vm Tech Sa Cardiac assistance device and its use
US5057117A (en) 1989-04-27 1991-10-15 The Research Foundation Of State University Of New York Method and apparatus for hemostasis and compartmentalization of a bleeding internal bodily organ
US5904690A (en) 1989-08-16 1999-05-18 Medtronic, Inc. Device or apparatus for manipulating matter
US4997431A (en) 1989-08-30 1991-03-05 Angeion Corporation Catheter
US4973300A (en) 1989-09-22 1990-11-27 Pioneering Technologies, Inc. Cardiac sling for circumflex coronary artery surgery
SU1734767A1 (en) 1990-01-31 1992-05-23 Томский Медицинский Институт Heart action assistance device
US5087243A (en) 1990-06-18 1992-02-11 Boaz Avitall Myocardial iontophoresis
US5131905A (en) 1990-07-16 1992-07-21 Grooters Ronald K External cardiac assist device
US5141515A (en) 1990-10-11 1992-08-25 Eberbach Mark A Apparatus and methods for repairing hernias
WO1992008500A1 (en) 1990-11-09 1992-05-29 Mcgill University Cardiac assist method and apparatus
US5119804A (en) 1990-11-19 1992-06-09 Anstadt George L Heart massage apparatus
US5169381A (en) 1991-03-29 1992-12-08 Snyders Robert V Ventricular assist device
US5197978B1 (en) 1991-04-26 1996-05-28 Advanced Coronary Tech Removable heat-recoverable tissue supporting device
AU662342B2 (en) 1991-05-16 1995-08-31 3F Therapeutics, Inc. Cardiac valve
US5571215A (en) 1993-02-22 1996-11-05 Heartport, Inc. Devices and methods for intracardiac procedures
US5584803A (en) 1991-07-16 1996-12-17 Heartport, Inc. System for cardiac procedures
US5150706A (en) * 1991-08-15 1992-09-29 Cox James L Cooling net for cardiac or transplant surgery
US5344385A (en) 1991-09-30 1994-09-06 Thoratec Laboratories Corporation Step-down skeletal muscle energy conversion system
US5290217A (en) 1991-10-10 1994-03-01 Earl K. Sipes Method and apparatus for hernia repair
US5524633A (en) 1991-11-25 1996-06-11 Advanced Surgical, Inc. Self-deploying isolation bag
US5192314A (en) 1991-12-12 1993-03-09 Daskalakis Michael K Synthetic intraventricular implants and method of inserting
US5333624A (en) 1992-02-24 1994-08-02 United States Surgical Corporation Surgical attaching apparatus
CA2089999A1 (en) 1992-02-24 1993-08-25 H. Jonathan Tovey Resilient arm mesh deployer
WO1993017635A1 (en) 1992-03-04 1993-09-16 C.R. Bard, Inc. Composite prosthesis and method for limiting the incidence of postoperative adhesions
US5352184A (en) 1992-03-12 1994-10-04 Uresil Corporation Reservoir for enclosing and retrieving body specimens
US5456711A (en) 1992-05-15 1995-10-10 Intervascular Inc. Warp knitted carotid patch having finished selvedged edges
US5766246A (en) 1992-05-20 1998-06-16 C. R. Bard, Inc. Implantable prosthesis and method and apparatus for loading and delivering an implantable prothesis
CA2098896C (en) 1992-06-30 2005-03-29 H. Jonathan Tovey Specimen retrieval pouch and method for use
US5383840A (en) 1992-07-28 1995-01-24 Vascor, Inc. Biocompatible ventricular assist and arrhythmia control device including cardiac compression band-stay-pad assembly
US5279539A (en) 1992-08-17 1994-01-18 Ethicon, Inc. Drawstring surgical pouch and method of use for preventing ovarian adhesions
US5256132A (en) 1992-08-17 1993-10-26 Snyders Robert V Cardiac assist envelope for endoscopic application
US5336254A (en) 1992-09-23 1994-08-09 Medtronic, Inc. Defibrillation lead employing electrodes fabricated from woven carbon fibers
US5814097A (en) 1992-12-03 1998-09-29 Heartport, Inc. Devices and methods for intracardiac procedures
EP0600140A1 (en) 1992-12-04 1994-06-08 SULZER Medizinaltechnik AG Container for the packaging of a hollow endoprosthesis
US5356432B1 (en) 1993-02-05 1997-02-04 Bard Inc C R Implantable mesh prosthesis and method for repairing muscle or tissue wall defects
US6125852A (en) 1993-02-22 2000-10-03 Heartport, Inc. Minimally-invasive devices and methods for treatment of congestive heart failure
US5797960A (en) 1993-02-22 1998-08-25 Stevens; John H. Method and apparatus for thoracoscopic intracardiac procedures
DE4317752C2 (en) 1993-05-27 1997-10-16 Peter Dr Feindt Device for supporting cardiac function
US6155968A (en) 1998-07-23 2000-12-05 Wilk; Peter J. Method and device for improving cardiac function
US5800334A (en) 1993-06-17 1998-09-01 Wilk; Peter J. Intrapericardial assist device and associated method
US5533958A (en) 1993-06-17 1996-07-09 Wilk; Peter J. Intrapericardial assist device and associated method
US5385528A (en) 1993-06-17 1995-01-31 Wilk; Peter J. Intrapericardial assist device and associated method
AU686206B2 (en) 1993-07-12 1998-02-05 Regents Of The University Of California, The Soft tissue augmentation apparatus
US5385156A (en) 1993-08-27 1995-01-31 Rose Health Care Systems Diagnostic and treatment method for cardiac rupture and apparatus for performing the same
US5460962A (en) 1994-01-04 1995-10-24 Organogenesis Inc. Peracetic acid sterilization of collagen or collagenous tissue
WO1995018593A1 (en) 1994-01-10 1995-07-13 Cardassist Incorporated Ventricular assist device
US6165210A (en) * 1994-04-01 2000-12-26 Gore Enterprise Holdings, Inc. Self-expandable helical intravascular stent and stent-graft
US5507779A (en) 1994-04-12 1996-04-16 Ventritex, Inc. Cardiac insulation for defibrillation
US5509428A (en) 1994-05-31 1996-04-23 Dunlop; Richard W. Method and apparatus for the creation of tricuspid regurgitation
US5582616A (en) 1994-08-05 1996-12-10 Origin Medsystems, Inc. Surgical helical fastener with applicator
US5593424A (en) 1994-08-10 1997-01-14 Segmed, Inc. Apparatus and method for reducing and stabilizing the circumference of a vascular structure
US5433727A (en) 1994-08-16 1995-07-18 Sideris; Eleftherios B. Centering buttoned device for the occlusion of large defects for occluding
US5749839A (en) 1994-08-18 1998-05-12 Duke University Direct mechanical bi-ventricular cardiac assist device
US6331188B1 (en) * 1994-08-31 2001-12-18 Gore Enterprise Holdings, Inc. Exterior supported self-expanding stent-graft
US5545210A (en) 1994-09-22 1996-08-13 Advanced Coronary Technology, Inc. Method of implanting a permanent shape memory alloy stent
US5534024A (en) 1994-11-04 1996-07-09 Aeroquip Corporation Intraluminal stenting graft
US5603337A (en) 1994-12-05 1997-02-18 Jarvik; Robert Two-stage cardiomyoplasty
US5900245A (en) * 1996-03-22 1999-05-04 Focal, Inc. Compliant tissue sealants
US5849005A (en) 1995-06-07 1998-12-15 Heartport, Inc. Method and apparatus for minimizing the risk of air embolism when performing a procedure in a patient's thoracic cavity
GB9510624D0 (en) 1995-05-25 1995-07-19 Ellis Dev Ltd Textile surgical implants
US6132438A (en) 1995-06-07 2000-10-17 Ep Technologies, Inc. Devices for installing stasis reducing means in body tissue
US5647380A (en) 1995-06-07 1997-07-15 W. L. Gore & Associates, Inc. Method of making a left ventricular assist device
US5800528A (en) 1995-06-13 1998-09-01 Abiomed R & D, Inc. Passive girdle for heart ventricle for therapeutic aid to patients having ventricular dilatation
US5713954A (en) 1995-06-13 1998-02-03 Abiomed R&D, Inc. Extra cardiac ventricular assist device
US5836311A (en) 1995-09-20 1998-11-17 Medtronic, Inc. Method and apparatus for temporarily immobilizing a local area of tissue
DE19538796C2 (en) 1995-10-18 1999-09-23 Fraunhofer Ges Forschung Device for supporting the heart function with elastic filling chambers
US5948019A (en) 1995-10-25 1999-09-07 Medtronic, Inc. Heart valve suturing ring with surface coating to inhibit tissue ingrowth
US6833408B2 (en) * 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
US5957977A (en) 1996-01-02 1999-09-28 University Of Cincinnati Activation device for the natural heart including internal and external support structures
US6592619B2 (en) 1996-01-02 2003-07-15 University Of Cincinnati Heart wall actuation device for the natural heart
US5782746A (en) 1996-02-15 1998-07-21 Wright; John T. M. Local cardiac immobilization surgical device
CA2197614C (en) 1996-02-20 2002-07-02 Charles S. Taylor Surgical instruments and procedures for stabilizing the beating heart during coronary artery bypass graft surgery
US5727569A (en) 1996-02-20 1998-03-17 Cardiothoracic Systems, Inc. Surgical devices for imposing a negative pressure to fix the position of cardiac tissue during surgery
US5853422A (en) 1996-03-22 1998-12-29 Scimed Life Systems, Inc. Apparatus and method for closing a septal defect
US6533805B1 (en) 1996-04-01 2003-03-18 General Surgical Innovations, Inc. Prosthesis and method for deployment within a body lumen
US5979456A (en) 1996-04-22 1999-11-09 Magovern; George J. Apparatus and method for reversibly reshaping a body part
DK0914102T3 (en) * 1996-05-24 2006-01-09 Angiotech Pharm Inc Preparations and methods for treating or preventing diseases of the body canals
US5855601A (en) 1996-06-21 1999-01-05 The Trustees Of Columbia University In The City Of New York Artificial heart valve and method and device for implanting the same
CA2211305A1 (en) 1996-07-25 1998-01-25 Jose A. Navia Epicardial immobilization device
US6059750A (en) * 1996-08-01 2000-05-09 Thomas J. Fogarty Minimally invasive direct cardiac massage device and method
US5824028A (en) 1996-09-20 1998-10-20 The Uab Research Foundation Line electrode oriented relative to fiber direction
US6123662A (en) * 1998-07-13 2000-09-26 Acorn Cardiovascular, Inc. Cardiac disease treatment and device
US5702343A (en) * 1996-10-02 1997-12-30 Acorn Medical, Inc. Cardiac reinforcement device
US6071303A (en) 1996-12-08 2000-06-06 Hearten Medical, Inc. Device for the treatment of infarcted tissue and method of treating infarcted tissue
US6050936A (en) 1997-01-02 2000-04-18 Myocor, Inc. Heart wall tension reduction apparatus
US6077214A (en) 1998-07-29 2000-06-20 Myocor, Inc. Stress reduction apparatus and method
US6045497A (en) 1997-01-02 2000-04-04 Myocor, Inc. Heart wall tension reduction apparatus and method
US6183411B1 (en) 1998-09-21 2001-02-06 Myocor, Inc. External stress reduction device and method
US6406420B1 (en) 1997-01-02 2002-06-18 Myocor, Inc. Methods and devices for improving cardiac function in hearts
US5961440A (en) 1997-01-02 1999-10-05 Myocor, Inc. Heart wall tension reduction apparatus and method
US6148233A (en) 1997-03-07 2000-11-14 Cardiac Science, Inc. Defibrillation system having segmented electrodes
US6166184A (en) 1997-08-18 2000-12-26 Medtronic Inc. Process for making a bioprosthetic device
US6117979A (en) 1997-08-18 2000-09-12 Medtronic, Inc. Process for making a bioprosthetic device and implants produced therefrom
US6390976B1 (en) 1997-09-17 2002-05-21 Origin Medsystems, Inc. System to permit offpump beating heart coronary bypass surgery
US6007486A (en) 1997-10-07 1999-12-28 Ethicon Endo-Surgery, Inc. Tissue stabilization device for use during surgery having a segmented shaft
US5984864A (en) 1997-10-07 1999-11-16 Ethicon Endo-Surgery, Inc. Tissue stabilization device for use during surgery
US6190408B1 (en) 1998-03-05 2001-02-20 The University Of Cincinnati Device and method for restructuring the heart chamber geometry
US6214047B1 (en) 1998-03-10 2001-04-10 University Of Cincinnati Article and method for coupling muscle to a prosthetic device
US6095968A (en) 1998-04-10 2000-08-01 Cardio Technologies, Inc. Reinforcement device
US6110100A (en) 1998-04-22 2000-08-29 Scimed Life Systems, Inc. System for stress relieving the heart muscle and for controlling heart function
US6024096A (en) 1998-05-01 2000-02-15 Correstore Inc Anterior segment ventricular restoration apparatus and method
US6085754A (en) 1998-07-13 2000-07-11 Acorn Cardiovascular, Inc. Cardiac disease treatment method
US6547821B1 (en) 1998-07-16 2003-04-15 Cardiothoracic Systems, Inc. Surgical procedures and devices for increasing cardiac output of the heart
US6260552B1 (en) 1998-07-29 2001-07-17 Myocor, Inc. Transventricular implant tools and devices
US6818018B1 (en) * 1998-08-14 2004-11-16 Incept Llc In situ polymerizable hydrogels
US6360749B1 (en) * 1998-10-09 2002-03-26 Swaminathan Jayaraman Modification of properties and geometry of heart tissue to influence heart function
US6685627B2 (en) 1998-10-09 2004-02-03 Swaminathan Jayaraman Modification of properties and geometry of heart tissue to influence heart function
EP1121176A1 (en) 1998-10-15 2001-08-08 Cardio Technologies, Inc. Passive defibrillation electrodes for use with cardiac assist device
US6587734B2 (en) 1998-11-04 2003-07-01 Acorn Cardiovascular, Inc. Cardio therapeutic heart sack
US6169922B1 (en) 1998-11-18 2001-01-02 Acorn Cardiovascular, Inc. Defibrillating cardiac jacket with interwoven electrode grids
US6230714B1 (en) 1998-11-18 2001-05-15 Acorn Cardiovascular, Inc. Cardiac constraint with prior venus occlusion methods
US6432039B1 (en) 1998-12-21 2002-08-13 Corset, Inc. Methods and apparatus for reinforcement of the heart ventricles
US6076013A (en) * 1999-01-14 2000-06-13 Brennan; Edward F. Apparatus and methods for treating congestive heart failure
US6155972A (en) 1999-02-02 2000-12-05 Acorn Cardiovascular, Inc. Cardiac constraint jacket construction
US6701929B2 (en) * 1999-03-03 2004-03-09 Hany Hussein Device and method for treatment of congestive heart failure
US6312725B1 (en) * 1999-04-16 2001-11-06 Cohesion Technologies, Inc. Rapid gelling biocompatible polymer composition
US6673088B1 (en) 1999-05-18 2004-01-06 Cardica, Inc. Tissue punch
US6192280B1 (en) 1999-06-02 2001-02-20 Medtronic, Inc. Guidewire placed implantable lead with tip seal
US6633780B1 (en) * 1999-06-07 2003-10-14 The Johns Hopkins University Cardiac shock electrode system and corresponding implantable defibrillator system
US6569082B1 (en) 1999-08-10 2003-05-27 Origin Medsystems, Inc. Apparatus and methods for cardiac restraint
US20040102804A1 (en) 1999-08-10 2004-05-27 Chin Albert K. Apparatus and methods for endoscopic surgical procedures
US6179791B1 (en) 1999-09-21 2001-01-30 Acorn Cardiovascular, Inc. Device for heart measurement
US6193648B1 (en) 1999-09-21 2001-02-27 Acorn Cardiovascular, Inc. Cardiac constraint with draw string tensioning
US6287250B1 (en) 1999-09-21 2001-09-11 Origin Medsystems, Inc. Method and apparatus for cardiac lifting during beating heart surgery using pericardial clips
US6174279B1 (en) 1999-09-21 2001-01-16 Acorn Cardiovascular, Inc. Cardiac constraint with tension indicator
US6702732B1 (en) 1999-12-22 2004-03-09 Paracor Surgical, Inc. Expandable cardiac harness for treating congestive heart failure
US6293906B1 (en) * 2000-01-14 2001-09-25 Acorn Cardiovascular, Inc. Delivery of cardiac constraint jacket
WO2001067985A1 (en) 2000-03-10 2001-09-20 Paracor Surgical, Inc. Expandable cardiac harness for treating congestive heart failure
US6425856B1 (en) * 2000-05-10 2002-07-30 Acorn Cardiovascular, Inc. Cardiac disease treatment and device
US6902522B1 (en) * 2000-06-12 2005-06-07 Acorn Cardiovascular, Inc. Cardiac disease treatment and device
US6730016B1 (en) * 2000-06-12 2004-05-04 Acorn Cardiovascular, Inc. Cardiac disease treatment and device
US6951534B2 (en) 2000-06-13 2005-10-04 Acorn Cardiovascular, Inc. Cardiac support device
US6572533B1 (en) 2000-08-17 2003-06-03 Acorn Cardiovascular, Inc. Cardiac disease treatment and device
US6887192B1 (en) * 2000-09-08 2005-05-03 Converge Medical, Inc. Heart support to prevent ventricular remodeling
US6673009B1 (en) 2000-11-08 2004-01-06 Acorn Cardiovascular, Inc. Adjustment clamp
US6547716B1 (en) 2000-11-28 2003-04-15 Abiomed, Inc. Passive cardiac restraint systems having multiple layers of inflatable elements
US6755779B2 (en) * 2000-12-01 2004-06-29 Acorn Cardiovascular, Inc. Apparatus and method for delivery of cardiac constraint jacket
US6564094B2 (en) 2000-12-22 2003-05-13 Acorn Cardiovascular, Inc. Cardiac disease treatment and device
US6620095B2 (en) 2000-12-22 2003-09-16 Syde A. Taheri Cradle-assisted myocardial repair and treatment
US6575921B2 (en) 2001-02-09 2003-06-10 Acorn Cardiovascular, Inc. Device for heart measurement
US6738674B2 (en) 2001-07-25 2004-05-18 Oscor Inc. Implantable coronary sinus lead with mapping capabilities
US6884812B2 (en) * 2001-08-31 2005-04-26 Aventis Pharma Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
EP1424958A2 (en) * 2001-09-10 2004-06-09 Paracor Medical, Inc. Cardiac harness
US7060023B2 (en) 2001-09-25 2006-06-13 The Foundry Inc. Pericardium reinforcing devices and methods of using them
US6685620B2 (en) 2001-09-25 2004-02-03 The Foundry Inc. Ventricular infarct assist device and methods for using it
US6695769B2 (en) * 2001-09-25 2004-02-24 The Foundry, Inc. Passive ventricular support devices and methods of using them
US7022063B2 (en) * 2002-01-07 2006-04-04 Paracor Medical, Inc. Cardiac harness
US7181272B2 (en) 2002-04-22 2007-02-20 Medtronic, Inc. Cardiac restraint with electrode attachment sites
US6682475B2 (en) 2002-06-11 2004-01-27 Acorn Cardiovascular, Inc. Tension indicator for cardiac support device and method therefore
US20050059855A1 (en) 2002-11-15 2005-03-17 Lilip Lau Cardiac harness delivery device and method
US7736299B2 (en) 2002-11-15 2010-06-15 Paracor Medical, Inc. Introducer for a cardiac harness delivery
US7189203B2 (en) 2002-11-15 2007-03-13 Paracor Medical, Inc. Cardiac harness delivery device and method
US20050283042A1 (en) 2003-03-28 2005-12-22 Steve Meyer Cardiac harness having radiopaque coating and method of use
CA2530429A1 (en) * 2003-07-10 2005-01-27 Paracor Medical, Inc. Self-anchoring cardiac harness
US7235042B2 (en) * 2003-09-16 2007-06-26 Acorn Cardiovascular, Inc. Apparatus and method for applying cardiac support device
US20050137673A1 (en) 2003-11-07 2005-06-23 Lilip Lau Cardiac harness having electrodes and epicardial leads
US7155295B2 (en) 2003-11-07 2006-12-26 Paracor Medical, Inc. Cardiac harness for treating congestive heart failure and for defibrillating and/or pacing/sensing
WO2005046746A2 (en) 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE29517393U1 (en) * 1995-11-03 1996-02-01 Hohmann Claas Dr Med Pericardial prosthesis
US6416459B1 (en) * 1997-06-21 2002-07-09 Acorn Cardiovascular Inc. Bag for at least partially enveloping a heart
US6482146B1 (en) * 2000-06-13 2002-11-19 Acorn Cardiovascular, Inc. Cardiac disease treatment and device

Also Published As

Publication number Publication date
EP1677702A1 (en) 2006-07-12
US20060094925A1 (en) 2006-05-04
US7022063B2 (en) 2006-04-04
US20070021652A1 (en) 2007-01-25
CA2541890A1 (en) 2005-05-26
US20040147805A1 (en) 2004-07-29
US7976454B2 (en) 2011-07-12
JP2007512040A (en) 2007-05-17
US7097613B2 (en) 2006-08-29

Similar Documents

Publication Publication Date Title
US7097613B2 (en) Cardiac harness
US6425856B1 (en) Cardiac disease treatment and device
US8801598B2 (en) Cardiac support device
US7214181B2 (en) Septum attached ventricular support
US6567699B2 (en) Defibrillating cardiac constraint
US6537203B1 (en) Cardiac disease treatment and device
US20110166413A1 (en) Compliant cardiac support device
US7174896B1 (en) Method and apparatus for supporting a heart

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2541890

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004818599

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006538143

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004818599

Country of ref document: EP